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1.  Zusammenfassung 
 
Peroxisome proliferator aktivierter Rezeptor γ Coaktivator-1 (PGC-1) bezeichnet eine Familie von 
Coaktivatoren, bestehend aus PGC-1α, PGC-1β und PRC
1,2,3
. Diese binden an Transkriptionsfaktoren wie 
beispielsweise nukleäre Rezeptoren und induzieren so die Expression von Zielgenen, welche 
mitochondrielle Biogenese
4
, Glukose Aufnahme in die Zelle
5
 sowie Gluconeogenese
6
, oxidative 
Phosphorylierung (OXPHOS)
7,8
 und β- Oxidation von Fettsäuren
9
 steuern. PGC-1 wurde erstmals in 
braunem Fettgewebe
1
 identifiziert und wurde seitdem vor allem in Geweben mit hohem Energieumsatz 
nachgewiesen (Skelettmuskel, Herz, Leber, Gehirn, Niere), wo es als Antwort auf einen physiologischen 
Stressor (körperliche Aktivität, Kälteeinwirkung, Nahrungskarenz) exprimiert wird
10,11,12,1,13
. Deshalb sind 
Expression und Funktion von PGC-1α gewebespezifisch. Derzeit ist PGC-1α das am besten untersuchte 
aller PGC-1s. 
 
Die Retina ist ein Gewebe mit sehr hohem Energiebedarf, da dort die Photorezeptoren Licht in ein vom 
Gehirn verwertbares Signal umwandeln
14
. Die Rolle von PGC-1α in der Netzhaut wurde bis jetzt jedoch 
nicht analysiert:  
Das erste Projekt befasste sich deshalb mit der Expression und Funktion von PGC-1α und teilweise auch 
der von PGC-1β in der Maus Retina: Zuerst analysierten wir dort das basale Expressionsmuster von 
PGC-1α und PGC-1β. Anschliessend wurden Mäuse, welchen das PGC-1α Gen fehlt (PGC-1α Knockout 
= KO) und Wildtyp (WT) Kontrolltiere mit hochfrequentem Licht bestrahlt beziehungsweise dunkel 
exponiert. Dann wurden Morphologie (Histologie), Funktion (ERG- Elektroretinogramm) und 
Genexpression (Microarray, semi- quantitative real time PCR) der Mausretinae analysiert. Die PGC-1α 
KO Mäuse wiesen einen starken Lichtschaden der Photorezeptorstrukturen sowie verstärkte Apoptose auf 
im Vergleich zu den WT Kontrolltieren. Analog dazu wurde bei einigen lichtexponierten KO Tieren eine 
veränderte ERG Antwort festgestellt. Die Microarrayergebnisse zeigten eine Expressionsminderung von 
DNA Reparatur- und Phototransduktionsgenen sowie verstärkte Expression von Entzündungs- und 
Apoptosegenen. Abschliessend konnten wir in einem in vitro Modell zeigen, dass die Ueberexpression 
von PGC-1α Apoptose verringert.  
 
Zur spezifischen Funktion von PGC-1β im Skelettmuskel ist ebenfalls wenig bekannt: Wir versuchten 
deshalb im zweiten Projekt, dessen Rolle im Glucose Stoffwechsel und der Bestimmung der 
Skelettmuskelfasertypen zu klären. Des weiteren hatten wir uns zum Ziel gesetzt, die PGC-1β 
spezifischen Zielgene in diesem Gewebe zu identifizieren. Aus diesem Grund versuchten wir, eine 
skelettmuskelspezifische Knockdown Maus für PGC-1β zu generieren: Unterschiedliche short hairpin 
RNAs (shRNAs) und Kontrollen, sogenannte scrambled shRNAs gegen Maus PGC-1β wurden 
entsprechend verschiedener Designmodi generiert (shRNA vs shRNA-mir) und deren Knockdown 
Effizienz und Spezifität wurde anschliessend in Zellkultur getestet. Die geeignetste shRNA wurde dann in 
einen Vektor kloniert, welcher für die Herstellung von Adeno-Assoziiertem Virus (AAV) verwendet wurde. 
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Wir produzierten AAV des Serotyps AAV2/6, da dieser einen spezifischen Tropismus für Skelettmuskel 
besitzt. Injektionsmenge, Weg und Dauer bis zur Expression der shRNA wurde mittels eines Virus, der 
grün fluoreszierendes Protein (GFP) exprimiert, optimiert. Der shRNA enthaltende Virus wurde dann in 
den Maus tibialis anterior Muskel injiziert und nach einer Inkubationszeit von 3 Wochen extrahiert. 
Anschliessend wurde der Muskel auf die Expression von Entzündungsmarkern analysiert. Semi- 
quantitative real time PCR Analysen zeigten ebenfalls, dass PGC-1β als auch dessen Zielgene signifikant 
in ihrer Expression reduziert waren. Ein in vivo Test eines skelettmuskelspezifischen Promotors, welcher 
die Expression der shRNA steuern sollte, führte jedoch zu keiner signifikanten Reduktion von PGC-1β.  
 
Zusammengefasst konnten wir zeigen, dass PGC-1α in lichtinduzierter Apoptose in der Retina eine 
protektive Rolle einnimmt (Projekt 1).  
In Projekt 2 zeigten wir, dass die Reduktion von PGC-1β im Skelettmuskel zu einer verminderten 
Expression von Genen führt, welche OXPHOS steuern.  
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2. Summary 
 
Peroxisome proliferator-activated receptor γ coactivator- 1 (PGC-1) designates a family of coactivators 
consisting of PGC-1α, PGC-1β and PRC
1,2,3
. By associating with transcription factors like nuclear 
receptors, they induce transcription of target genes that are responsible for mitochondrial biogenesis
4
, 
glucose uptake
5
, gluconeogenesis
6
, oxidative phosphorylation
7,8
 and β-oxidation of fatty acids
9
. Originally 
identified in brown adipose tissue
1
, these coactivators are predominately expressed in tissues with high 
energy requirements (skeletal muscle, heart, liver, brain, kidney) upon stimulation with physiological 
stressors (exercise, cold, fasting)
10,11,12,1,13
. PGC-1’s expression and function is therefore highly tissue 
specific. PGC-1α is to date the best studied of all family members.  
 
One of the tissues high in energy demand is the retina; its photoreceptors convert light into a signal that 
can be interpreted by the brain
14
. However, thus far the physiological role of PGC-1α has never been 
studied there. In the first project of this thesis, we consequently analyzed PGC-1α and to a certain extent 
also PGC-1β expression and function in mouse retina: We first assessed expression patterns of PGC-1α 
and PGC-1β. Second, we subjected mice with a global deletion of the PGC-1α gene (PGC-1α knockout = 
KO) and wildtype (WT) control mice to high intensity light compared to a dark setting and studied their 
retinae’s morphology (histology), function (electroretinogram) and gene expression levels (microarray, real 
time PCR). We found the PGC-1α KO mice to display increased apoptosis and disrupted retinal 
photoreceptor structure compared to the wildtype (WT) control animals upon light exposure. The 
corresponding light damage could also be confirmed by ERG in some animals. Microarray analysis 
revealed downregulation of DNA repair and phototransduction as well as an upregulation of inflammatory 
and apoptotic pathways, respectively in the KO animals. Finally, we confirmed in an in vitro setting that 
overexpression of PGC-1α helped alleviate apoptosis. 
 
The role of PGC-1β in skeletal muscle has not been thoroughly studied either: More specifically, we 
wanted to address its role in glucose metabolism/ insulin sensitivity and fiber type composition as well as 
to identify exclusive target genes of PGC-1β in this tissue in the second project. For this purpose, we 
aimed at generating a skeletal muscle specific knockdown mouse: Different small hairpin RNAs (shRNAs) 
and control, scrambled shRNAs against mouse PGC-1β were designed according to different design 
principles (shRNA vs shRNA-mir) and tested for their knockdown efficiency and specificity in cell culture. 
The most promising one was then inserted into a vector backbone used to generate adeno-associated 
virus (AAV). We decided to produce the AAV serotype AAV2/6, as it displays specific tropism for skeletal 
muscle (AAV2/6). Injection quantity, route and duration until onset of shRNA expression were optimized 
with a virus expressing green fluorescent protein (GFP). The virus carrying shRNA was then injected into 
the mouse tibialis anterior muscle and after 3 weeks of incubation time analyzed for inflammatory gene 
expression. Semi- quantitative real time PCR analysis revealed that expression of PGC-1β as well as of 
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its downstream target genes was significantly reduced. In vivo testing of a skeletal muscle specific 
promoter, however, did not lead to a significant reduction of PGC-1β levels.  
 
In summary, we showed that PGC-1α has a protective role in light induced apoptosis in the retina 
(project1).  
In project 2, we showed that a reduction of PGC-1β in skeletal muscle leads to diminished expression of 
genes implicated in OXPHOS.  
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3.  Introduction 
 
3.1.  The PGC-1 family of coactivators 
 
Eukaryotic gene expression is a tightly regulated process that is governed by altering the state of 
chromatin: It is either decondensed by histone acetyl- transferases (HATs) or condensed by histone 
deacetylases (HDACs). Upon decondensation, chromatin is rendered more accessible and allows for 
transcription to occur
15
.  
Transcription factors bind to DNA promoter or enhancer regions and thus steer the rate of conversion from 
DNA to RNA. Thereby, they associate with chromatin remodeling cofactors (coactivators or corepressors) 
which either have intrinsic HAT or HDAC properties or recruit either of these. Cofactors also associate 
with various other chromatin remodeling enzymes. This process either drives or impedes transcriptional 
activity. Cofactors split into two classes:  
Class I cofactors enzymatically modify DNA tertiary structure, by acetylation (class I coactivators) or by 
deacetylation of histones (class I corepressors). Class II cofactors (coactivators or corepressors) 
associate with RNA polymerase II, however, they lack the enzymatic activity to modify histones. As such, 
they require interaction with class I coactivators
16,17
.  
The peroxisome proliferator activated receptor γ coactivator – 1 (PGC-1) designates a family of such class 
II coactivators that regulate transcription
1
.  
The PGC-1 family is composed of three members present in all mammals: PGC-1α, PGC-1β and PGC-1 
related coactivator (PRC) (for reviews see
18,19
).  
 
3.2.  Structural features of PGC-1α 
 
PGC-1α, PGC-1β and PRC share common structural modules that enable their tight interaction with the 
transcriptional machinery: 
 
These include first, an activation domain (AD) at the N-terminus which recruits several HAT complexes 
like the 3’-5’- cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB)- binding 
protein (CBP), p300 and steroid receptor coactivator-1(SRC-1)
20
. Three LXXLL motifs locate adjacent to 
the AD and enable binding of many transcription factors.  
Second, the C-terminus contains a RNA binding domain that attracts the thyroid receptor-associated 
protein/ vitamin D receptor-interacting protein/ mediator complex (TRAP/ TRIP). This complex facilitates 
direct interaction with the transcription initiation machinery
21
. This region also interacts with the switch/ 
sucrose non-fermentable (SWI/SNF) chromatin-remodeling complex through its interaction with the 
mammalian chromatin remodeling associated factor BAF60a
22
.  
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Third, adjacent to this domain lies the highly conserved nuclear localization signal as well as serine- 
arginine rich region that coordinates transcription and pre-mRNA splicing jointly with the RNA binding 
domain
23,24
. 
Fourth, the mid region between the two termini features a repression domain where silent information 
regulator T1 (SIRT1) and the MYB binding protein (P160) can attach
19
. Interestingly, this region is only 
present in PGC-1α and PGC-1β, yet absent in PRC (Fig.1). 
 
These structural elements equip PGC-1 with the necessary tools to attract and assemble various 
chromatin remodeling and histone-modifying enzymes and thus steer transcription actively. In line with its 
function as transcriptional activator, it can also deter repressor proteins from attaching
25
. 
 
 
 
Fig.1: (A): Sequence homology of PGC-1α, PGC-1β and PRC (B) Structural domains and protein complexes 
associating with PGC-1α: red= activation domain, yellow= arginine/ serine rich domain, purple= RNA binding 
domain, green= transcriptional repression domain. 
Source: 
19
 
 
This crucial role of PGC-1 in transcriptional regulation is substantiated by its high degree of conservation 
across chordate species, including primates, rodents, ruminants, birds, amphibians, and fishes. Even in 
Drosophila, a PGC-1 homologue called Spargel was recently identified
26
. Nevertheless, PGC-1 fulfills 
different functions in different species, such as lower and in higher vertebrates. Such a functional 
ramification across lineages results from duplication and insertion events
27
. 
 
3.3.  The discovery of PGC-1α 
 
The first function attributed to PGC-1α was that of being a transcriptional coactivator of peroxisome 
proliferator- activated receptor γ (PPARγ)
1
. PPARγ is a member of the PPAR nuclear receptor family. 
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PPARγ regulates adipogenesis in brown adipose tissue (BAT) and white adipose tissue (WAT): PPARγ’s 
differential activation of transcriptional targets in these two tissues revealed that PGC-1α is an interaction 
partner of PPARγ in BAT
1,28
.  
 
Three major findings helped to elucidate the main role of PGC-1α:  
First, BAT is able to perform thermogenesis owing to its increased number of mitochondria compared to 
WAT. Second, PGC-1α was identified in highly oxidative tissues
4,29,30
. Third, ectopic overexpression of 
PGC-1α was shown to drive the expression of mitochondrial genes, both nuclear and mitochondrially 
encoded
4
, leading to increased mitochondrial biogenesis and oxidative phosphorylation (OXPHOS).  
 
3.4.  Binding partners 
 
In subsequent studies, PGC-1α was found to be a coactivator of a myriad of different classes of 
transcription and chromatin remodeling factors: 
 
Nuclear receptors 
 
A well-studied class of transcription factors is nuclear receptors: These are activated upon binding of 
ligands like steroid or thyroid hormones to their surface and act as transcription factors on genes that are 
implicated in metabolic and developmental processes
17
: PGC-1α coactivates thyroid hormone receptors 
(TR)
1
, estrogen receptors (ER)
1
 and estrogen related receptors (ERRs)
31,8
 which promote OXPHOS and 
are also involved in enhancing angiogenesis. Besides the PPARs
1,32
, liver X receptors (LXR)
33
 are also 
crucial in promoting fatty acid oxidation and transport and are also binding partners of PGC-1α.  
The involvement of PGC-1α in dopaminergic neuron and osteoblast regulation is attested by its 
association with nuclear receptor subfamily 1(NURR1)
34
.  
Retinoid X receptors (RXR) α, β and γ are involved in retinoic acid signaling and also constitute members 
of the nuclear receptor family bound by PGC-1α
35
.  
For activation by PGC-1α to occur, some nuclear receptors need not be bound to a ligand, as is the case 
of ERRα, hepatocyte nuclear factor 4 (HNF4) or farnesoid X receptor (FXR)
36,37,38
. These nuclear 
receptors are implicated in oxidative phosphorylation, insulin release and bile acid synthesis steps, 
respectively. Unliganded transcriptional activation ensures rapid response to physiological requirements.  
 
Chromatin remodeling factors 
 
As a recruiting agent for factors involved in transcription, PGC-1α also regulates chromatin remodeling 
factors like host cell factor C1 (HCFC1)
39
 and BRG1-associated factor 60a (BAF60A)
22
. 
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Transcription factors 
 
Among the classical transcription factors controlled by PGC-1α are nuclear respiratory factors 1 and 2 
(NRF1 and NRF2), primary drivers of mitochondrial biogenesis as well as myocyte enhancer factor2 
(MEF2) which steers skeletal muscle fiber type determination
3,40
. It also associates with GA-binding 
protein transcription factor (GABP) which controls cytochrome C oxidase expression and mitochondrial 
transcription factor A (TFAM) which participates in mitochondrial genome replication
41
.  
Another important target of PGC-1α is the forkhead/ winged helix protein family member (FOXO1) which 
drives hepatic gluconeogenesis
42
. 
 
PGC-1α thus activates transcription factors that control processes as diverse as mitochondrial biogenesis 
and remodeling, skeletal muscle fiber type determination, angiogenesis, hepatic gluconeogenesis and 
fatty acid oxidation. 
Its most prominent role, however, is to steer transcription factors implicated in OXPHOS, which garnered 
PGC-1α the name of master regulator of oxidative metabolism.  
 
Subsequent analysis revealed that PGC-1α is highly expressed in tissues with high energy requirements 
like skeletal muscle, heart, liver, brain, liver, pancreas, kidney, BAT and WAT
40,12,43,6,11,44,1
.  
Stressors like exercise, cold or fasting seem to be the common denominators of the events that lead to 
PGC-1α activation across different tissues
10,11,12,1,13
.  
As PGC-1α has tissue specific expression patterns/ function and its role is best studied in skeletal muscle, 
we will look at its upstream and downstream regulation in this tissue:  
 
3.5.  PGC-1α in skeletal muscle 
 
3.5.1. Mechanisms upstream of PGC-1α 
 
3.5.1.1. Transcriptional regulation  
 
In skeletal muscle, physiological stimuli like physical activity, changes in temperature and metabolic 
demands partly converge in similar metabolic outcomes (Fig.2):  
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Fig.2: Regulation of PGC-1α transcription: The PGC-1α promoter contains binding sites for MEF2, FOXO1, ATF2 
and CREB. These factors promote PGC-1α transcription. They are, in turn, modulated by different signaling pathways: 
insulin, cytokines, exercise, cold and glucagon. P= phosphorylation site. GLGNR= glucagon receptor 
Source: 
45
. 
 
During physical activity, an action potential in the central nervous system (CNS) signals to the α-
motorneuron and then to the skeletal muscle, where calcium release finally mediates muscle contraction, 
a process where actin and myosin filaments slide within each other by consuming adenosine triphosphate 
(ATP). Calcium activates calcium/ calmodulin dependent protein kinase (CaMKIV) and calcineurin A 
(CnA). CnA then activates MEF2C and MEF2D leading to transcription of PGC-1α which is further 
enhanced by a feedback stimulation of MEF2C and MEF2D by PGC-1α
46
. CaMKIV is phosphorylated by 
calcium and then activates PGC-1α via CREB
11
. 
 
Physical activity also leads to release of interleukins (IL-6, IL-8, IL-15, brain-derived neurotrophic factor 
BDNF, fibroblast growth factor-21 FGF21 and leukemia inhibitory factor LIF) some of which are implicated 
in glucose homeostasis and β-oxidation of fatty acids
47
. These factors are also called cytokines, if 
released from the muscle, they are termed myokines. Myokines as well as exercise itself promote 
activation of p38 MAPK. P38 MAPK in turn activates MEF2 and activating transcription factor2 (ATF2) 
which induce PGC-1α
48
. 
 
During exercise, the adenosine monophosphate (AMP)/ ATP ratio in the cell is high meaning that the cell 
is energy deprived: AMP activated protein kinase (AMPK) is thus activated to restore energy homeostasis 
by increasing fat oxidation, mitochondrial biogenesis and glucose uptake. AMPK transcription is 
specifically induced by the AMPK activator AICAR and AMPK likewise activates PGC-1α via 
phosphorylation
49,50
.  
 
The lack of energy encountered during physical activity triggers a rise in glucagon levels and protein 
kinase A (PKA) activation in liver. Likewise, cold exposure, sensed by β-adrenergic signaling receptor (β3-
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AR) leads to increased cAMP and PKA activity
1
. PKA then targets CREB which in turn activates PGC-1α 
expression
1,51
. This effect is potentiated via stimulation of p38 MAPK
52
.  
 
Insulin, the antagonist of glucagon favors activation of anabolic pathways. As PGC-1α is primarily 
implicated in catabolic pathways, it seems that insulin inhibits PGC-1α transcription: Insulin signals to AKT 
leading to phosphorylation of FOXO1. Thereupon, FOXO1 is excluded from the nucleus and cannot 
promote transcription of PGC-1α any more
53
. Contrary to this finding, Puigserver et al found that FOXO1 
does not activate, but is coactivated by PGC-1α
42
.  
 
3.5.1.2. Posttranslational regulation  
 
Besides transcriptional regulation, posttranslational modification of PGC-1α confers a second, faster 
regulation mode to this coactivator. The respective residue that undergoes modification determines if 
PGC-1α is activated or repressed (Fig.3):  
 
 
Fig.3: Posttranslational modifications of PGC-1α  
Source:
45
. 
 
Among the first posttranslational modifications of PGC-1α to be identified was phosphorylation:  
AMPK
54
, PKA and p38MAPK
55
 activate the coactivator upon phosphorylation, whereas the serine- 
threonine protein kinase AKT and Cdc2-like kinase2 (CLK2)
56
 repress PGC-1α’s activity. 
 
Phosphorylation of PGC-1α by AMPK is a prerequisite for activation of PGC-1α: Upon energy deprivation, 
the cellular levels of nicotinamide dinucleotide (NAD+) increase through AMPK. This leads to increased 
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activity of silent information regulator 1 (SIRT1) which deacetylates and thus activates PGC-1α
57
. This 
deacetylation must be preceded by phosphorylation of PGC-1α by AMPK. Upon caloric excess, the 
acetyltransferase general control of amino acid synthesis5 (GCN5) acetylates PGC-1α which has an 
inhibitory effect
45
. 
 
PGC-1α is known to have a short half- life of about 2.3 hours
55
. Proteasomal degradation of PGC-1α in 
this context plays a huge role via glycogen synthase kinase 3 β (GSK3β)
58
.  
 
Recently, PGC-1α has been found to be sumoylated which decreases its activity via a possible interaction 
with the corepressor receptor interacting protein 140 (RIP140)
59
. 
 
PGC-1α also undergoes methylation by protein arginine methyl-transferase1 (PRMT1) enhancing its 
transcription as well as glycosylation by O-linked N-acetlyglucosamine (O-GlcNAc) transferase (OGT). 
The functional role of the latter modification, though, is not known to date
60,61
.  
 
3.5.1.3. Splicing mediated regulation  
 
Other than the rapid control of PGC-1α via posttranslational modification or the slower, transcriptional 
control of PGC-1α, there is a third option of modulating its activity:  
Assembly of different exons yields mRNAs that are different in size and exon composition: These different 
splice forms may be the result of specific stimuli: PGC-1α was first found to be subject to alternative 
splicing mechanisms in BAT in response to cold
62
. A similar splicing pattern was identified in skeletal 
muscle: The resulting splice variant was exercise- induced, lacked exon8 and yielded a functional, albeit 
smaller PGC-1α protein
10
. Some years on, PGC-1α was found to harbor two versions of exon1: exon1a 
and exon1b: Coupling of either of these exons with exon2 generates diverse isoforms of PGC-1α which 
are stress inducible in skeletal muscle, BAT or liver
63,64
. 
Recently, an N-terminal splice variant of PGC-1α, containing a stop codon after exon6 was described. 
This variant seems to be relatively stable and its cellular localization (nuclear vs cytoplasmic) and thus 
activity are determined by phosphorylation
65
.  
 
3.5.2. Mechanisms downstream of PGC-1α 
 
Increased levels of PGC-1α in skeletal muscle entail a myriad of different physiological outcomes; some of 
the most important ones are as follows: 
 
Exercise means increased ATP demand: Cells can increase their ATP levels via glycolysis, OXPHOS and 
β-oxidation of fatty acids: The latter two require oxygen but supply the organism with a higher yield of ATP 
than non-oxidative forms of energy generation:  
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OXPHOS and oxidation of fatty acids take place in mitochondria: Upon exercise, these organelles 
reorganize by fusion or fission and increase their number and size to increase performance. The increase 
in number, termed mitochondrial biogenesis is potently stimulated by PGC-1α which also  upregulates 
mRNA content of components of the electron transport chain, like cytochrome oxidases COXI, COXII, 
COXIV, ATP synthase and cytochrome c (CYT c)
40
. These are both mitochondrially (e.g. COXI, COXII) as 
well as nuclear- encoded (e.g. COXIV, CYT c). 
Mitochondria are organized into subsarcolemmal (SSL) and intermyofibriallar (IMF) mitochondria that 
differ in their location, biochemical properties and speed of substrate utilization
66
.  
 
Generation of metabolites for OXPHOS takes place in the tricarboxylic acid (TCA) cycle: This cycle 
requires acetyl-CoA which is delivered by β-oxidation of fatty acids and glycolysis and thus couples 
carbohydrate and fat metabolism: In this cycle, PGC-1α increases citrate synthase (CS) activity
13
. To 
further increase TCA cycle activity, PGC-1α also mediates uptake of free fatty acids (FFAs) from the blood 
into the muscle via the CD36 fatty acid translocase (CD36), it upregulates carnitine palmitoyltransferase 1 
(CPT1) and medium-chain acyl-coenzyme A dehydrogenase (MCAD) which mediate β-oxidation of fatty 
acids
67
.  
Another argument for preferential oxidation of FFAs for ATP generation is that PGC-1α increases glucose 
uptake via the GLUT4 transporter
5
. Yet, the glucose is not shuttled into glycolysis but into generation of 
lipids via fatty acid synthase (FAS). These lipids concomitantly serve as substrates for β-oxidation of 
FFAs
68
. PGC-1α thus seems to be involved in catabolic and anabolic skeletal muscle metabolism. 
Furthermore, PGC-1α promotes glycogen synthesis to assure energy provision for sustained exercise
69
.   
 
Increased OXPHOS necessitates increased oxygen supply to the skeletal muscle: PGC-1α thus promotes 
angiogenesis and increases myoglobin levels in this tissue
40,70
. Myoglobin contains an oxygen binding 
prosthetic group called heme. PGC-1α increases heme biosynthesis by inducing the expression of its rate 
limiting enzyme, δ-aminolevulinate synthase1 (ALAS-1)
71
.   
 
OXPHOS also leads to increased levels of reactive oxygen species (ROS), which are generated through 
incomplete reduction of an oxygen molecule: The resulting oxygen radical is detoxified via enzymes like 
superoxide dismutase (SOD2) whose transcript levels are increased by PGC-1α
72
. PGC-1α also employs 
a second strategy in reducing cellular ROS levels: It increases mRNA expression of uncoupling proteins 
UCP2 and UCP3
73
. These dissipate the proton gradient created during oxidative phosphorylation. 
Decreased ROS confer a higher degree of protection against DNA damage and inflammatory events to 
the cell: Mice overexpressing PGC-1α in skeletal muscle display reduced levels of tumor necrosis factor α 
(TNFα) and interleukin-6 (IL-6) in serum and skeletal muscle
72
. 
 
Given the numerous metabolic adaptations to stress that PGC-1α expression enables, it is 
understandable that this coactivator is rapidly inducible upon exercise in rodents and humans
10,74
. Yet, a 
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mouse model of sustained, skeletal muscle specific overexpression of PGC-1α mediates not only 
metabolic, but also functional changes:  
 
Structurally, skeletal muscle is composed of different fiber types according to their metabolic profile and 
contractile isoform: It is made up of so called fast-twitch and slow-twitch fibers: Fast-twitch fibers in 
rodents contain type IIB and IIX myosin heavy chains (MHCs) that mainly use glycolysis for energy 
generation. They share a white phenotype, low myoglobin concentration and tire rapidly. They thus are 
equipped for short term, acute bouts of exercise. Rodent slow-twitch fibers contain type I and IIA MHCs 
and mainly use OXPHOS for energy provision. They appear red in color, have high myoglobin content and 
are effective in sustained, long term exercise
75
.  
Upon skeletal muscle specific overexpression, PGC-1α promotes the conversion of fast into of slow-twitch 
fibers
40
 in mice. Consequently, these mice have increased running endurance, yet reduced peak 
performance
67,69
. 
 
PGC-1α improves endurance muscle performance not only in the basal state, but is also beneficial in 
disease models: First, its ectopic expression prevents muscle fiber atrophy caused by denervation
76
. 
Second, in a mouse model of Duchenne muscular dystrophy, characterized by a mutation in the 
dystrophin gene, PGC-1α ameliorates muscle histology, serum creatine kinase (CK) levels and running 
performance
77
. 
 
In summary, PGC-1α is a versatile coactivator that mediates a vast program of skeletal muscle plasticity 
(Fig.4). (See 
41
 for a more detailed review).  
 
 
Fig.4: PGC-1α induces a pleiotropic response in skeletal muscle upon exercise 
Source: 
41
. 
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4. The role of PGC-1α in retina 
 
4.1. Introduction 
 
4.1.1. Retina structure 
  
 
 
 
The vertebrate retina translates the information of a photon of light into an electrical signal. It is a complex 
layer at the innermost part of the eyeball and is made up of 8 distinct cell types that allow for visual 
perception. Six of these cell types are neuronal cells: Ganglion, amacrine, bipolar, horizontal cells (= 
interneurons) and rod and cone photoreceptors.  
Two retinal cell types are non-neuronal: Müller cells and retinal pigment epithelial (RPE) cells. 
The 8 distinct cell types are distributed across functionally diverse compartments: Three of these 
compartments are rich in cell bodies and consequently, cell nuclei: The outer nuclear layer (ONL), inner 
nuclear layer (INL) and the ganglion cell layer (GCL). 
The vertebrate retina is inverted, meaning that light penetrates the eye at the neuronal cell layers until it 
reaches the photoreceptors which process the signal. This information is then conveyed back to the 
interneurons which in turn transmit it to other neuronal cells and to the brain
14
: 
 
The RPE locates next to the chorioidea that contains blood vessels responsible for nutrient supply of the 
retina. Phototransduction takes place in the adjacent rod and cone photoreceptors, that are specialized in 
mediating vision in darkness/ mesopic conditions and light conditions, respectively. Photoreceptors are 
composed of an outer segment (OS) made up of stacks of membrane disks. These disks contain cone or 
Fig.5: Retina structure: abbreviations: left hand side: cell layers; right 
hand side: cell types; 
RPE= retinal pigment epithelium 
OS= outer segment  
IS= inner segment  
ONL= outer nuclear layer  
OPL= outer plexiform layer 
INL= inner nuclear layer 
IPL= inner plexiform layer 
GCL= ganglion cell layer 
NFL= nerve fiber layer 
BM= basal membrane 
P= pigment epithelial cell 
R= rod 
C= cone 
H= horizontal cell 
Bi= bipolar cell 
M= Müller cell 
A= amacrine cell 
G= ganglion cell 
Ax= axon 
 
Source: 
http://de.wikipedia.org/w/index.php?title=Datei:Retina.jpg&filetimestamp
=20080814113451 
 
light 
NFL 
Epiretinal layer 
 
L 
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rod opsin linked to 11-cis retinal. Upon illumination, the 11-cis retinal moiety changes its confirmation to 
all-trans retinal and dissociates from opsin. This process is termed “bleaching”. All-trans retinal is shuttled 
into the RPE which regenerates 11-cis retinal for use in the OS. The RPE also phagocytes used 
photoreceptor disks that are not functional any more in a process called “disk shedding”. The 
photoreceptor OS is connected to the inner segment (IS) via a connecting cilium. The IS contains 
mitochondria and endoplasmic reticulum and thus constitutes the photoreceptors’ metabolically active 
compartment.  
The cell bodies of rod and cone photoreceptors convey information via glutamate release to bipolar cells 
and then to ganglion cells. Glutamate has either activating (on bipolar cells) or repressing (off bipolar cells) 
effects on them. Horizontal cells mediate vision when the photoreceptors’ periphery is illuminated. As 
such, they are at the interface between photoreceptors and bipolar cells. Amacrine cells are mediators 
between rod bipolar and on/ off bipolar cells. Rod and cone signaling thus converges in activation of on/ 
off bipolar cells and ganglion cells. Müller cells are glia cells that span across the retina and thus occupy a 
stabilizing function. The nerve fiber layer (NFL) contains several axons of ganglion cells and lies adjacent 
to the epiretinal layer which forms a tight delimitation against the vitreous body
14
. 
 
4.1.2. Phototransduction 
 
Photoreceptor rods and cones mediate vision in a similar way: Rods are more light- sensitive and better 
equipped for visualizing movement. Cones are less light sensitive yet generate color vision. While rods 
contain only one type of rhodopsin, there are three different, wavelength-specific cone types in humans: L-
cones (blue), M-cones (green) and S-cones (red)
78
.  
 
 
Fig.6: Phototransduction process in the retina in light (simplified) 
Depicted is an outer membrane disk in a rod. Step 1: photon (hv) is absorbed and activates rhodopsin R by 
conformational change in the disk membrane to R*. Step 2: Next, R* makes repeated contacts with transducin G, 
catalyzing its activation to G* by the release of bound GDP in exchange for GTP. Step 3: G* binds inhibitory γ 
subunits of the phosphodiesterase (PDE) activating its α and β subunits. Step 4: Activated PDE hydrolyzes cyclic 
guanosine monophosphate (cGMP) to 5’cGMP. cGMP levels fall which closes cyclic nucleotide gated channels 
(Na
+
/Ca
2+
 channels), the cell hyperpolarizes, transmitter release is decreased. Step 5: Guanylyl cyclase (GC) restores 
cGMP levels.  
Source: http://commons.wikimedia.org/wiki/File:Phototransduction.png 
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4.1.2.1. In darkness 
 
Photoreceptor cells dispose of different ion channels to mediate vision by changing their membrane 
potential: 
cGMP gated sodium channels enable sodium inflow into the cell and thus depolarize it. Nongated 
potassium channels lead to an outflow of potassium, thus hyperpolarizing the cell.  
In darkness, photoreceptors are depolarized through an inward flow of sodium: This mechanism triggers 
the opening of calcium channels and the release of vesicles containing the neurotransmitter glutamate into 
the synaptic cleft. Photoreceptors thus signal to bipolar cells via glutamate which likewise transmit the 
signal to ganglion cells. ON bipolar cells hyperpolarize in response to high glutamate levels whereas OFF 
bipolar cells depolarize. Thus, in darkness, ON bipolar cells are inhibited and OFF bipolar cells are 
activated
78
. 
 
4.1.2.2. In light 
 
Initiation 
In light, phototransduction occurs via the photopigment Rhodopsin (rods) or Cone opsin (cones). It 
consists of the molecule opsin bound to 11-cis retinal. Upon interaction with a photon of light, 11-cis retinal 
undergoes isomerization into all-trans retinal which cannot accommodate into the opsin binding pocket 
any more. Consequently, opsin dissociates as meta-rhodopsin II and activates the G protein transducin. 
The GDP bound transducin dissociates from guanine diphosphate (GDP) and binds guanine triphosphate 
(GTP) with its α subunit while the β and γ subunits dissociate. Transducin activates phosphodiesterase 
(PDE) which cleaves cyclic guanine monophosphate (cGMP) into 5’GMP. Decreasing cGMP levels lead to 
closure of sodium channels which hyperpolarizes the cell. Voltage gated calcium channels close and 
calcium levels drop. In response, glutamate levels also drop as they require calcium for vesicle fusion. 
Low glutamate levels cause depolarization of ON bipolar cells and hyperpolarization of OFF bipolar cells
78
.  
 
Termination 
The visual cycle is terminated via GTPase activating protein (GAP) which transforms GTP into GDP, 
halting the action of the PDE. Guanylyl cyclase activating protein (GCAP) dissociates from its bound 
calcium ions and activates guanylyl cyclase (GC) which transforms 5’GMP into cGMP. This increase in 
cGMP levels reopens the cell’s sodium and calcium channels.  
In parallel, the decrease in calcium levels during phototransduction leads to dissociation of calcium from 
recoverin and rhodopsin kinase. Consequently, rhodopsin kinase phosophorylates meta-rhodopsinII, 
deactivating it. Arrestin further deactivates meta-rhodopsinII and restores the dark current
78
. 
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Regeneration (Visual cycle) 
All-trans retinal is reduced to all-trans retinol and is then shuttled to the RPE where it is recharged: It is 
first esterified by lecithin-retinol acyltransferase (LRAT) and then converted to 11-cis retinal by the 
isomerohydrolase RPE65. Consequently, it is shuttled back to the photoreceptor for resuming the 
phototransduction process. 
 
4.1.3. PGC-1α in retina 
 
The implication of PGC-1 in visual function has not been thoroughly studied thus far, yet several cues 
warrant its analysis in retina: 
 
PGC-1α and PGC-1β are primarily expressed in tissues with high energy requirements (see chapter 3.4 
and recent review
79
). The retina is one of the most energy demanding organs per gram of tissue
80
.  
 
PGC-1α and PGC-1β are expressed in a circadian- rhythm specific fashion throughout the day
81,82
. PGC-
1α governs transcription of the clock gene BMAL1, whose ablation leads to defective retinal activity in 
response to a light flash
83
. 
 
PGC-1α is reduced in age and metabolic conditions like type II diabetes in skeletal muscle
84
.These 
conditions also predispose towards development of retinal pathologies like age-related macular 
degeneration (AMD) and diabetic retinopathy, respectively
85
. AMD involves increased generation of 
reactive oxygen species (ROS), inflammatory response and endoplasmic reticulum associated stress 
leading to apoptosis, all of which are associated with decreased PPARγ levels
86
. PGC-1α, on the other 
hand, is known to promote ROS detoxification as well as decreasing expression levels of inflammatory 
genes
72
. Furthermore, photoreceptor phagocytosis in the retina involves PPARγ activation
87
. 
 
 
4.1.4. Apoptotic pathways 
 
Apoptosis or programmed cell death is a highly regulated process: It is required during development as 
well as cellular stress situations to ensure tissue viability and function. Impaired as well as increased 
apoptotic signaling can be implicated in a variety of diseases (cancer, autoimmune disease, 
neurodegenerative diseases)
88,89
. Stimuli like DNA damage, temperature insults (heat or cold exposure), 
hypoxia, oxidative stress, virus infection or energy deprivation can lead to induction of apoptosis via a 
defined sequence of events
90
. Unlike necrosis, where the cell contents is released in an uncontrolled 
fashion into the cytosol and thus promotes inflammation and compromise of neighboring cells, apoptosis 
occurs in distinct phases: the cell shrinks, shows deformation and loses contact to its adjacent cells, 
chromatin condenses, the plasma membrane blebs or buds, and finally the cell is fragmented into 
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compact membrane-enclosed structures, called 'apoptotic bodies' which contain cytosol, the condensed 
chromatin, and organelles
91,92
. 
 
 
Fig.7: Intrinsic and extrinsic apoptotic pathways 
Source: 
93
. 
 
The pathways leading to apoptosis are diverse (Fig.7):  
 
The intrinsic pathway starts with internal cellular insults like hypoxia, DNA damage or energy deprivation. 
The tumor suppressor p53 is subsequently phosphorylated and stabilized via the DNA damage checkpoint 
mediators Ataxia Telangiectasia mutated protein (ATM) and Checkpoint Factor-2 (CHK2). P53 then 
represses anti apoptotic BCL2. BCL2-associated X protein (BAX), BCL2 antagonist (BAK), NADPH 
oxidase activator 1 (NOXA) and BH3 interacting domain death agonist (BID) are further targets of p53 
which propagate the apoptotic signal. Their apoptogenic properties lead to release of SMAC/ DIABLO 
which inactivates the inhibitor of apoptosis (IAP) molecule. In parallel, cytochrome c is extruded by the 
mitochondria which binds to apoptotic peptidase activating factor 1 (APAF1) and to pro-caspase 9, 
generating the “apoptosome”. As a consequence, caspases 3, 6 and 7 ultimately execute apoptosis via 
cleavage of cytosolic and nuclear proteins
94,93
. 
 
The extrinsic pathway commences with binding of a death ligand to a death receptor located on the 
damaged cell’s surface. Different ligands have been characterized, ranging from Fas Ligand (FASL) or 
TNF related apoptosis inducing ligand (TRAIL)
95,96
. 
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Typically, this leads to ceramide release and lipid raft fusion which results in large scale clustering of the 
death receptors. Several apoptotic proteins like FAS associated death domain (FADD) then bind to the 
receptors which triggers recruitment of caspases 8 and 10. These caspases then integrate with the 
intrinsic pathway via activation of BH3 interacting domain death agonist (BID)
95
.  
 
Besides intrinsic and extrinsic pathways, there are also alternative apoptotic pathways that do not involve 
caspase activation: Among the non caspase proteases are the calcium dependent calpains, cathepsins 
and serine proteases like granzyme A. Among caspase independent endonucleases there are 
Cyclophyline A/ apoptosis inducing factor (AIF), Granzyme A Activated DNase (GAAD), leucocyte 
elastase inhibitor (LEI) 
88
.  
Programmed cell death may also involve mechanisms of autophagy which is a degradation mechanism for 
cell organelles, ubiquitin-proteasomal degradation steps or tissue specific mechanisms as cell shedding or 
cornification
88,97
.  
 
In conclusion, apoptosis is not a one canonical process but involves an interplay of diverse mechanisms 
which may be tissue specific. 
 
4.1.4.1. Apoptosis in retina 
 
Apoptosis in the retina occurs as a result of degenerative diseases that are acquired (like AMD, glaucoma 
and diabetic retinopathy) or hereditary conditions (like Retinitis pigmentosa or Leber’s congenital 
amaurosis)
98,99
, retinal development and physiological stressors (excessive light exposure, ROS). All of 
these stimuli lead to apoptosis of retinal cells. According to the employed stimulus, apoptosis varies in 
time of onset, severity and duration and nature of cells that are primarily affected (e.g. photoreceptors in 
retinitis pigmentosa versus ganglion cells in glaucoma)
100
. Owing to this multitude of stimuli, retinal 
apoptosis does not only involve the classical intrinsic and extrinsic pathways
88
:  
Exposure to excessive amounts of light is an established model for studying photoreceptor apoptosis. 
Contrary to disease models, light exposure can be well dosed and is a monofactorial model:  
Different molecules are involved in the light induced apoptotic induction, transduction, execution and 
clearance phases, respectively:  
Light damage induction requires a functional visual cycle: This cycle is interrupted in the absence of 11-cis 
retinal and the photoreceptors are resistant to light damage: Absence of RPE65, which regenerates 11-cis 
retinal thus prevents light damage induced apoptosis
101
. In accordance with that, absence of Rhodopsin 
prevents light induced apoptosis
101
.  
Likewise, absence of the retinoid chaperone cellular retinaldehyde-binding protein (CRALBP) which 
fosters rhodopsin regeneration protects mice from light damage
102
.  
The amount of light absorption by rhodopsin is also critical in determining how much damage occurs in the 
light- exposed retina: As blue light likely regenerates rhodopsin from its bleaching intermediates, it can 
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provide a higher number of bleachable rhodopsin molecules than green light: Blue light exposure thus 
causes more light damage
103
.  
Compromise in termination of the phototransduction cascade via ablation of rhodopsin kinase and/ or 
arrestin also renders mouse retina more vulnerable to light damage
104,105
.  
Transducin- deficient mice are as sensitive as WT mice towards acute bright light exposure, however, 
prolonged moderate light exposure is not harmful for these animals
105
.  
Consequently, damage induced by acute light exposure is mediated by rhodopsin bleaching
101
 whereas 
damage by moderate light exposure requires a functioning phototransduction process
105
. 
 
The light induced death signal is propagated via the transcription factor activator protein1 (AP-1). AP-1 
consists of different members of the c-FOS or c-FOS and c-JUN proteins which partly fulfill redundant 
functions. c-FOS was shown to be involved in light induced apoptosis
106
. 
Interestingly, the classical apoptotic protein, p53, does not seem to be involved in light-induced apoptosis 
in retina
107
. 
 
The execution and termination phases in retinal apoptosis may be mediated in part by caspases. Caspase 
inhibition however was not shown to be protective
108
. Most likely, caspases are important in in apoptosis 
during retinal development whereas caspase independent apoptosis seems to be associated with retinal 
disease conditions
100
: Retinal cell death may also occur via autophagy or ubiquitin- proteasomal 
degradation
88
. 
Protection strategies against light induced retinal cell death target the above mentioned phases: 
Inhibition of nitric oxide synthase (NOS) is a very effective tool in the early stage of apoptosis
108
. 
In the late stage of apoptosis, besides a range of growth factors and erythropoietin
109
, one of the most 
important protective responses to light induced retinal apoptosis in Müller cells is the induction of leukemia 
inhibitory factor (LIF). Upon light insult, it activates JAK-STAT signaling (JAK= janus kinase2, STAT1 and 
3= signal transducers and activators of transcription1 and 3)
110
. Its absence leads to accelerated retinal 
degeneration
111
.  
 
4.1.4.2. Apoptosis and PGC-1α  
 
PGC-1α has been linked to apoptosis in different contexts and tissues: 
 
In skeletal muscle, absence of PGC-1α is associated with reduced content of IMF and SSL mitochondria 
as well as reduced CYT c mRNA expression levels
112
. However, CYT c release from subsarcolemmal 
mitochondria of PGC-1α KO mice is increased 
113
.  
Likewise, p53 knockout animals have reduced mitochondrial content and diminished protein levels of 
PGC-1α. Subsarcolemmal CYT c release is increased, whereas intramyofibrillar CYT c release is 
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decreased. Total apoptosis measured by nucleosomal fragmentation, however, is decreased in this 
setting
114
.  
As no other measurement of apoptosis was used in
113
 and no apoptotic trigger was employed in both
113
 
and
114
, it is hard to pinpoint the implication of PGC-1α in skeletal muscle apoptosis. 
 
An apoptotic trigger was employed by Liang et al who looked at the effects of potassium deprivation in 
cerebellar granule neurons leading to c-Jun kinase (JNK9) activation: The increase in this inflammatory 
mediator negatively regulates the PGC-1α promoter. PGC-1α overexpression on the other hand seems to 
decrease apoptosis
115
. 
 
During the course of this PhD project, Zheng et al showed that lovastatin, a cholesterol lowering drug, also 
influences the diabetic retina: Lovastatin decreases ROS production and displays anti-inflammatory 
effects, reduced Poly ADP ribose polymerase (PARP) and p38 MAPK protein levels correlating with 
increased PGC-1α levels
85
. 
 
In light of these data, it would be desirable to conclusively show in loss AND gain of function experiments 
what PGC-1α’s actual role in retinal apoptosis induction is, using a tissue- specific trigger. 
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4.2.  Project aims 
The role of PGC-1 in retina should thus be studied with regard to seven major questions: 
 
 Retinal expression patterns of PGC-1α and PGC-1β  
  
 Localization of PGC-1α and PGC-1β in the different retinal compartments 
 
 Relevance of PGC-1α and PGC-1β for retinal development 
 
 Expression of PGC-1α and PGC-1β in retinal disease models 
 
 Retinal response to a physiological stressor in the absence of PGC-1α as well as its functional 
and morphological analysis  
 
 Implication of PGC-1α in retinal apoptosis  
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Abstract 
 
The peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1) proteins are key regulators 
of cellular bioenergetics and are accordingly expressed in tissues with a high energetic demand. We now 
show that PGC-1α and PGC-1β are found at high levels in the mouse retina, most prominently in the 
photoreceptors. PGC-1α knockout mice suffer from a striking deterioration in retinal morphology and 
function upon detrimental light exposure. Gene expression analyses revealed dysregulation of all major 
pathways involved in retinal damage and apoptosis, repair and regeneration in the PGC-1α knockouts. 
The light- induced increase in apoptosis in vivo in the absence of PGC-1α was substantiated in vitro, 
where overexpression of PGC-1α showed strong anti-apoptotic effects. Finally, we found that retinal levels 
of PGC-1 expression are reduced in different mouse models for retinitis pigmentosa.  Our findings thus 
imply that PGC-1α might be an attractive target for therapeutic approaches targeted at retinal 
degeneration diseases. 
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Introduction 
 
The vertebrate retina translates information of a photon of light into an electrical signal. It is a complex, 7-
layered compartment at the innermost part of the eye and is made up of 8 distinct cell types, five of which 
are neuronal cells. Photons hit photosensitive cells (photoreceptors), which enable phototransduction by 
conformational change of the photopigment rhodopsin. Distinct photoreceptors allow for vision in light 
(cone cells) and dark (rod cells) conditions. Subsequent photopigment recovery occurs in the adjacent 
retinal pigment epithelium (RPE)
14
. The light information is transmitted from the photoreceptors via 
interneurons (amacrine cells, horizontal cells, bipolar cells) to ganglion cells, which then relay an electric 
action potential to the optical nerve and ultimately the visual cortex in the brain. 
 
PGC-1 (peroxisome proliferator-activated receptor γ coactivator-1) designates a family of coactivators that 
comprises PGC-1α, PGC-1β and PGC-1-related coactivator (PRC). These coactivators dock to specific 
nuclear receptors and other transcription factors, thereby promoting the transcription of target genes, for 
example those implicated in mitochondrial biogenesis and oxidative phosphorylation (OXPHOS)
19,18,116,117
. 
PGC-1α and PGC-1β are mainly expressed in tissues with a high energetic demand, such as skeletal 
muscle, liver, pancreas, heart, kidney, brain and brown adipose tissue (BAT)
19,18,116,117
. The expression of 
PGC-1α and PGC-1β is further regulated in these organs by developmental stimuli and physiological 
stressors like cold, fasting and exercise. PGC-1α and PGC-1β accordingly regulate tissue-specific 
functions such as adaptive thermogenesis in brown adipose tissue, gluconeogenesis in the liver or 
endurance exercise adaptation in skeletal muscle
19,18,116,117
.  
 
Interestingly, despite the well-established link between PGC-1 expression and cellular energetics, the 
expression and function of the PGC-1 coactivators in the retina, one of the most energy demanding 
vertebrate organs
80
, has not been studied so far, even though a number of cues warrant the analysis of 
this coactivator family in this organ. 
The high demand on ATP for physiological retinal function is assured by both glycolysis and oxidative 
phosphorylation: Neurotransmission relies on glycolysis, sodium transport employs glycolysis and 
oxidative phosphorylation, whereas phototransduction is mainly fuelled by oxidative phosphorylation to 
meet energetic demands
118
. In phototransduction, rods and cones are comparable in their energy 
expenditure in dark conditions, while cones have greater energy demands in the light
119
. Thus, most of the 
metabolic processes that are important for retinal function are most probably strongly regulated by the 
PGC-1 coactivators in analogy to other tissues, in particular substrate uptake, fatty acid oxidation and 
oxidative phosphorylation. 
 
Inversely, pathological conditions of the retina such as age-related macular degeneration and diabetic 
retinopathy are associated with excess generation of reactive oxygen species (ROS), inflammation and 
endoplasmic reticulum stress, which result in apoptosis and tissue degeneration
86,85
. PGC-1α affects 
these processes by promoting ROS detoxification
43
, ameliorating endoplasmic reticulum stress
120
 and 
modulating tissue as well as systemic inflammation
121,122
. Finally, photoreceptor outer segment renewal 
involves activation of PPARγ
87
, a functional interaction partner of the PGC-1 coactivators in various 
tissues
1
.  
 
Thus, to investigate the potential role of PGC-1α in the retina, we assessed the expression patterns of 
PGC-1α and PGC-1β in retinal development, adult retina and mouse models for degenerative retinal 
diseases. Furthermore, we investigated the consequences of genetic ablation of PGC-1α in the retina in 
terms of changes in gene expression, morphology and function in the basal, dark condition and upon light-
induced retinal stress and damage. Finally, we validated some of our findings in retinal cells ex vivo with 
acutely altered levels of PGC-1α. Our findings indicate a crucial role for PGC-1α in tissue protection, in 
part by inhibition of apoptosis. 
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Results 
 
PGC-1α and PGC-1β are highly expressed in murine retina 
 
Real-time qPCR-based expression analysis revealed highest PGC-1α and PGC-1β levels in tissues with 
a great energetic demand. Accordingly, PGC-1α and PGC-1β were found at elevated levels in skeletal 
and cardiac muscle, brain and kidney. Both coactivators were more moderately expressed in liver and 
lung. 
Strikingly, the highest expression levels of all tissues studied were observed in the retina for PGC-1α 
and PGC-1β (Fig. 1a). 
 
To assess the differential expression pattern of PGC-1α and PGC-1β in distinct retinal compartments, 
we used laser capture microdissection to separate the different retinal cell layers and subsequently 
quantified expression via qPCR. PGC-1α and PGC-1β showed their highest expression in the outer 
nuclear layer (ONL) that harbors rod and cone photoreceptors (Fig. 1b). Although markedly lower 
compared to ONL, expression of both coactivators was also found in the inner nuclear layer (INL), which 
contains bipolar, horizontal, amacrine and Müller glia cells, and the ganglion cell layer (GCL), where 
ganglion and amacrine cells are located (Fig. 1b). 
 
To distinguish between rod and cone-specific expression of the PGC-1 coactivators within the ONL, we 
determined PGC-1α and PGC-1β levels in neural retinal leucine zipper (Nrl) knockout animals, which 
lack rod photoreceptors but retain cone morphology and function
123
 and the rd10 mouse model where 
rod degeneration is followed by cone degeneration until all photoreceptors are lost by day 60 
124
. The 
significant reduction of PGC-1α and PGC-1β transcript levels in Nrl knockout mice (Fig. 1c) and the rd10 
animal model (Fig. 1d) implies that both coactivators are expressed in rods and cones. 
 
Genetic ablation of Pgc-1α does not compromise morphology and function in the dark adapted, 
unstressed mouse retina 
 
PGC-1α global knockout animals
125
 were used to study the function of PGC-1α in the retina. First, we 
analyzed basal morphology of 7 week- old PGC-1α knockout (KO) and C57 BL/6 WT control mice.  
Both KO and WT animals revealed an intact, regularly shaped retinal structure (Fig. 2a). To assess 
basal retinal function, the mice were kept in the dark and then subjected to an electroretinogram (ERG), 
which tracks the electrical responses of retinal cells to a light stimulus. The resulting a and b and waves 
reflect the function of the outer and inner layer, respectively. ERG responses were recorded in scotopic 
(darkness) and photopic (illuminated) conditions to analyze rod and cone function, respectively. In all of 
these experimental contexts, the PGC-1α KO mice showed regular a and b waves undistinguishable 
from the WT control animals (Fig. 2b). Finally, in addition to the morphological and functional studies, 
we investigated whether genetic ablation of the PGC-1α gene in the retina affects global gene 
expression patterns with gene expression microarrays. Gene ontological analysis revealed primarily a 
reduction in metabolic pathways in the KO animals, foremost oxidative phosphorylation and citrate cycle 
(Fig. 2c), similar to results in loss-of-function experiments with PGC-1α in other tissues. Inversely, 
cytoskeleton remodeling, transforming growth factor beta (Tgfβ) and Wnt signaling were the most 
prominent pathways expressed at a higher level in KO compared to WT mice (Fig. 2c). 
 
Absence of PGC-1α increases light-damage susceptibility 
 
While in most organs, the effects of genetic ablation on morphology and function are relatively mild, 
stress conditions like exercise, cold or fasting greatly exacerbate the phenotype of PGC-1α knockout 
mouse models
121,125
. Thus, triggered by our observation of a small effect of PGC-1α knockout on retinal 
morphology and function in the dark, we sought to study the repercussions of PGC-1α ablation after 
employing a physiological, retina-specific stressor. For this purpose, PGC-1α KO and WT control mice 
were exposed to 15.000 lux of white light for 2hrs, which corresponds to direct sun light exposure. After 
a 24hrs recovery period, morphologies of PGC-1α deficient and WT control retinae were analyzed. 
In stark contrast to the dark-adapted mice (Fig. 2), PGC-1α KO and WT control mice responded 
markedly differently to a strong light insult. First, most of the rod inner (RIS) and outer (ROS) segments 
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were completely destroyed and most nuclei were pyknotic in the ONL of PGC-1α KO mice (Fig. 3a). 
Thus, most photoreceptors have lost their light absorption (ROS) and energy-production (RIS) sites. In 
contrast, the corresponding regions in WT exhibited only occasional pyknotic nuclei (Fig. 3a) and only 
one out of six wild type animals showed measurable retinal damage, which, however, was still less 
intense than in PGC-1α KOs (data not shown). In either of the genotypes, the INL and GCL layers were 
unharmed consistent with previous data showing that light damage causes selective death of 
photoreceptor cells
101
 (Fig. 3a). 
 
 
 
Given the nature and extent of retinal degeneration observed in the KO animals, it seemed highly likely 
that these morphological changes would translate into loss of retinal function. Light- exposed PGC-1α 
KO mice displayed a blunted scotopic ERG compared to the WT mice with a significant reduction in b 
wave amplitude 10 days post insult (Fig. 3b). This timeframe was chosen as retina clears injured 
photoreceptors and returns back to a basal state within 10 days
88
. The photopic response in KO animals 
remained similar to WT mice, which is consistent with the notion that cones remain unharmed in an 
acute light- damage paradigm, at least at early timepoints after light damage
126
. 
 
Subsequent to the ERG analysis, animals were subjected to spectral domain optical coherence 
tomography (SD-OCT), which allow for highly sensitive cross sectional analysis of retinal layers, 
respectively, and thus reveal retinal detachment as well as delicate structural impairments. Cross 
sectional retinal analysis showed that the KO mice that had a reduced scotopic ERG response also 
displayed a thinning of the ONL compared to WT controls. (Fig. 3c- ABC). 
 
 
Light-exposed PGC-1α KO animals exhibit reduced expression of phototransduction genes, 
increased expression of apoptotic and inflammatory markers 
 
 
To elucidate the deficits in gene expression in the light-stressed PGC-1α KO animals, we compared 
gene expression microarrays of WT and KO mice in the control, dark-adapted state and after light 
exposure, respectively.  Interestingly, the influence of the environmental conditioning from dark to light 
exposure was similar in the two genotypes in regard to the number of regulated genes. However, most 
of the 2914 genes regulated in the KO animals between dark and light were different from the 2524 
genes in the WT animals or were modulated at a significantly higher level. Thus, light- exposed PGC-1α 
KO and WT mice differed in the expression of 1774 genes, 897 of which were elevated and 877 of which 
were decreased in KO compared to the WT mice, more than three times the number of genes as 
observed in the corresponding dark accommodated mouse comparison (Fig. 4a, Suppl. Fig. 1e). The 
top regulated genes (Suppl. Table 1a) and the most affected pathways (Suppl. Table 1b) that were 
downregulated in KO mice compared to WT animals still included metabolic processes as observed in 
the dark condition. Strikingly however, various key processes in retinal function, damage and repair, in 
particular visual perception, photoreceptor function, DNA damage and repair were now lower in the KO 
animals compared to controls (Fig. 4b, 4c and Suppl. Fig. 1a-c). Phototransduction pathway analysis 
showed that PGC-1α KO mice displayed diminished expression of retina specific genes in the 
illuminated state (for example KO light vs WT light: Nrl, Nr2e3, Arr3, Scn4a, Cnga1) (Fig. 4b, 4c, 
Suppl.Table 1b). Similarly, the expression of many anti-apoptotic genes was reduced in the animals 
with an ablated PGC-1α gene, including Fas (Fig. 4b, 4c and Suppl. Table 1). Inversely, many 
inflammatory and pro-apoptotic genes were expressed at a higher level in light-exposed KO mice 
compared to controls, such as Bcl2 and A2M, respectively (Fig. 4b, 4c).  
Interestingly, genes involved in extrinsic or intrinsic apoptosis were upregulated in the PGC-1α KO vs 
WT animals; however, no specific apoptotic pathway was preferentially affected (Suppl. Table 2a).  
Finally, only the WT animals exhibited an increase in oxidative phosphorylation gene expression pattern 
comparing dark adapted to light exposed mice (Supp. Table 1b: WTli vs WTda up; KOli vs KOda up).  
 
 
PGC-1α expression alleviates apoptosis in retinal cells 
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Light exposure of the retina leads to damage and induction of apoptotic pathways. Based on our 
observation in light exposed animals, we tested whether PGC-1α function is directly involved in the 
regulation of early events in photoreceptor apoptosis and we therefore quantified cell death in PGC-1α 
KO and WT control animals following light exposure. In this experimental context, the generation of free 
nucleosomes was detected in both genotypes, but at significantly higher levels in the PGC-1α KO than 
in the WT control animals (Fig. 5a). Thus, the deterioration of the KO retina upon light exposure involves 
an increase in apoptotic events. 
 
To circumvent the potentially confounding effects of a global, life-long absence of PGC-1α in the KO 
mice that may be compensated in vivo, we investigated the effect of acutely modulated PGC-1α in 
ARPE-19 cells, a retinal pigment epithelial cell line. 
In these cells, we studied cytochrome c release as an early event in intrinsic, mitochondria-related 
apoptosis. ARPE-19 cells were transduced with adenovirus encoding GFP as control or PGC-1α 
expression cassettes, respectively. Importantly, despite the induction of cytochrome c expression by 
PGC-1α that has been reported in other experimental contexts (Fig. 5b), no change in cytochrome c 
release was observed in ARPE-19 cells with ectopic elevation of PGC-1α (Fig. 5c). As expected, 
treatment of the ARPE-19 cells with actinomycin D or camptothecin caused elevated cytochrome c 
release and thus apoptosis in GFP-expressing control cells. However, when the cells were additionally 
expressing PGC-1α, this resulted in a significant reduction in cytochrome c release that was statistically 
undistinguishable from cytochrome c release in vehicle- treated control cells. (Fig. 5b). 
 
PGC-1α and PGC-1β are reduced in rd10 and VPP models of degenerative retinal disease 
 
A wide array of retinal disease conditions is associated with increased apoptosis of photoreceptors, 
including retinitis pigmentosa, a multi- genetic hereditary retinal disease that is caused by mutations in 
genes implicated in photoreceptor and RPE function. Retinitis pigmentosa (RP) causes progressive 
vision loss by the degeneration of rods and cones
99
. Animal models to study RP include the rd10, the 
VPP and the Nrl KO mouse
124,127,128
. Since apoptotic and other pathways involved in retinal damage in 
retinitis pigmentosa were affected by the PGC-1α gene knockout in light- exposed mice, we investigated 
whether the expression levels of PGC-1α were altered in these mouse models with age-dependent 
disease progression of retinal degeneration. In the WT animals, PGC-1α augmented with increasing age 
similar to Rho (Rhodopsin), a marker of rod differentiation. In contrast, after an initial rise, PGC-1α 
expression reverted back to initial levels in the rd10 mouse (Fig. 6a, b). A similar decrease was 
observed for PGC-1β expression in the rd10 animals, where PGC-1β levels remained consistently lower 
compared to those of WT animals, even after the initial spike of PGC-1β expression around the age of 
15 days (Fig. 6c). Any remaining amount of both coactivators was probably due to their presence in the 
GCL and INL which remained intact in all of the used models (Fig. 1b). 
The VPP mouse suffers from a degeneration of rods and cones caused by three rhodopsin mutations 
(V20G, P23H, and P27L [VPP])
127
. Both the rd10 and the VPP mouse models thus recapitulate the 
damage in rods and cones that is observed in human retinitis pigmentosa. Interleukin-1β (Il-1β), served 
as a control gene that is upregulated in the VPP mouse due to the inflammation in this model
129
 (Fig. 
6d), similar to what was shown for the inflammatory marker monocyte chemotactic protein 1(Mcp-1)
111
. 
Both PGC-1α and PGC-1β were expressed at a lower level in the VPP mouse compared to WT animals. 
Strikingly, convergence of both PGC-1α and PGC-1β expression in VPP and WT animals coincided with 
the relief of the inflammatory response in the VPP model implied by the strong decrease in Il-1β 
expression between day 42 and day 52. Thus, the apoptotic events seen in the VPP model that precede 
the inflammation directly correlated with reduced levels of PGC-1α and PGC-1β (Fig. 6d, e, f). 
Interestingly, PGC-1β was likewise reduced in the light- exposed PGC-1α knockout mice, which also 
exhibited retinal damage and dysfunction, as shown in the present manuscript (Supp. Fig. 1e). 
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Discussion 
 
The PGC-1 coactivators are key regulators of mitochondrial biogenesis and oxidative metabolism. Hence, 
our present observation of high expression of both PGC-1α and PGC-1β in the retina, a tissue with one of 
the highest energy demands, is not surprising. Moreover, the intraretinal expression pattern showing high 
levels of both coactivators in rod and cone photoreceptors reflects the high energetic requirement of 
phototransduction that to a large extent is met by oxidative phosphorylation
118
. Interestingly however, 
dark-adapted mice with an ablation of the PGC-1α gene in the retina display normal retinal morphology 
and function, even despite a notable reduction in metabolic gene expression in this experimental context. 
Lack of a prominent phenotype in PGC-1α loss-of-function settings in basal, unstressed conditions has 
also been observed in other organs in tissue-specific knockout mice
13,121,71
 and in global knockout 
animals
125,112
. Importantly, a more striking phenotypic dysregulation in these animal models is often 
induced by external stimuli such as fasting, cold exposure or exercise. Similarly, the absence of a 
functional PGC-1α gene has much more dramatic consequences in light-exposed compared to dark-
adapted animals. Light stress and the resulting cellular damage in the retina results in a cascade of events 
aimed at destruction of damaged cells through apoptosis, removal of cellular debris, repair of DNA 
damage and restoration of phototransduction through increased expression of cone- and rod-specific 
genes (Fig.6g). These processes require a considerable amount of energy, witnessed in the increased 
expression of genes implicated in oxidative phosphorylation in the WT light versus WT dark up 
(Suppl.Table 1b). For example, components of the NADH dehydrogenase (Ndufa) and the cytochrome c 
oxidase (Cox) complexes are upregulated in this context. The PGC-1α KO animals, however, likely fail to 
meet the increased energy need (Suppl.Table1: KO li vs WT li down) and thus restoration of tissue 
homeostasis and function is hampered (Fig. 6g). In addition, apoptosis and the inflammatory response are 
enhanced in light-damaged retinae of PGC-1α knockout animals, while DNA damage repair and 
photoreceptor recovery are impaired in these mice. Interestingly, a recent study analogously implied that 
PGC-1α dysregulation may be implicated in irradiation-caused DNA damage in the liver
130
. As a 
consequence, light-exposed retinae of PGC-1α knockout animals show morphological aberrations, 
specifically a destruction of the RIS and ROS and consequent thinning of the ONL. As a result, light 
perception is significantly impaired in these mice, as suggested in particular by the reduced the rod-
dependent, scotopic b-wave amplitude. Taken together, our data indicate an important role for PGC-1α in 
the protection against light-induced retinal damage. 
 
The interpretation of our data obtained in global PGC-1α knockout animals could potentially be hampered 
by several drawbacks of this model. First, total ablation of the PGC-1α gene in many cases results in 
different, sometimes diametrically opposed phenotypic changes compared to those in tissue-specific 
knockouts
131
. For example, hepatic gluconeogenesis is constitutively elevated in one global PGC-1α 
knockout mouse model
125
, whereas the fasting-dependent induction of gluconeogenesis is significantly 
blunted in liver-specific knockouts
71
. Similarly, fiber-type distribution in global knockout is unchanged 
compared to control mice, while AMP-dependent protein kinase (AMPK) is activated in this context
125,132
. 
In contrast, a fiber-type switch towards glycolytic muscle fibers has been observed in muscle-specific 
PGC-1α knockouts that also exhibit normal AMPK activation
13,121
. In both cases, the tissue-specific 
knockout models exhibit the phenotype that is expected based on in vivo gain-of-function experiments
40
,
6
. 
Second, in a global PGC-1α knockout mouse, PGC-1α is obviously not only absent in retinal cells, but 
also other structures involved in light perception and vision. For example, PGC-1α knockout animals suffer 
from marked neurodegenerative events in the central nervous system
125
. Neuronal deficits, in particular in 
the visual cortex where PGC-1α expression has been reported
133
, but also the optic nerve, would 
obviously also affect vision in these mice. Finally, it is difficult to interpret etiology and causality underlying 
the pathological phenotype in the global PGC-1α knockout animals with a life-long absence of a functional 
PGC-1α gene. To circumvent all of these potentially confounding problems of global, non-inducible PGC-
1α gene ablation and to test whether apoptosis is directly affected by PGC-1α and not altered as a 
consequence of an energy crisis, we tested whether acute modulation of PGC-1α levels in an isolated 
system of RPE cells recapitulates our observations made in light-exposed PGC-1α knockout mice 
exhibiting increased levels of apoptosis in vivo. Our experiments in the ARPE-19 cell line clearly show a 
strong anti-apoptotic effect of ectopically expressed PGC-1α against two different pharmacological 
triggers of apoptosis, actinomycin D and camptothecin. PGC-1α expression has been associated with 
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decreased apoptosis in different cellular contexts, including skeletal muscle
113
, aortic endothelial cells
134
 
and decreased retinal capillary cell apoptosis after statin treatment
85
. In contrast, PGC-1α regulates 
intestinal epithelial cell fate in part by promoting apoptosis in the intestinal epithelial surface
135
. We now 
show for the first time that loss-of-function of PGC-1α results in increased apoptosis in the retina in vivo 
and that increased levels of PGC-1α exert an anti-apoptotic effect in retinal pigment epithelial cells. 
 
Our tissue culture data thus not only confirm the direct involvement of loss-of-function of PGC-1α on 
apoptosis in the ONL in vivo, but together with the observation of reduced PGC-1α and PGC-1β 
expression in mouse models for retinitis pigmentosa also indicate that elevation of PGC-1α might be a 
valid approach to prevent retinal damage and also promote recovery in retinal diseases through increase 
in ATP generation. 
Future studies should thus aim at elucidating the therapeutic efficacy of normalization of PGC-1α levels 
with viral vectors or pharmacological tools on retinal degeneration in retinitis pigmentosa and other retinal 
pathologies. 
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Figure legends 
 
Figure 1. PGC-1α and PGC-1β are strongly expressed in rods and cones in the outer nuclear  
layer of the murine retina.  
Relative mRNA expression levels of PGC-1α and PGC-1β in different mouse tissues evaluated by semi- 
quantitative real time PCR. β- actin was used as housekeeping gene (HKG). P value was calculated using 
two tailed Student’s T test: * = p<0.05; *** =p<0.001. + SEM (a) Relative mRNA expression in different 
tissues from 3 month old wild type male C57BL/6j mice (TA= tibialis anterior). n=4 (b) Relative mRNA 
expression levels of PGC-1α and PGC-1β in different retinal layers from 3 month old wild type male 
C57BL/6 mice: ONL= outer nuclear layer, INL= inner nuclear layer, GCL= ganglion cell layer. n=4 (c) + (d) 
Relative mRNA expression levels of PGC-1α and PGC-1β in two retinal disease models: Retina was 
isolated from Nrl-/-, rd10 and age matched control C57BL/6j WT mice. n=3. (c) Expression of PGC-1α and 
PGC-1β in Nrl-/- mice at 2 months of age. Data were normalized against C57BL/6j WT mice. (d) 
Expression in rd10 mice at 5-6 months of age.  
 
Figure 2. Regular morphology and function in PGC-1α KO mouse retina. 
Dark adapted, 13 week old PGC-1α KO and C57BL/6j WT were subjected to morphological analysis and 
electroretinogram (ERG). (a) Representative retinal morphologic sections from the lower central retina of 
13 week old PGC-1α KO and C57BL/6j WT mice: RPE= retinal pigment epithelium, ROS= rod outer 
segments, RIS= rod inner segments, ONL= outer nuclear layer, INL= inner nuclear layer, GCL= ganglion 
cell layer. (b) [A] Scotopic (dark-adapted) and [B] photopic (light-adapted) single-flash ERGs with 
increasing light intensities recorded from PGC-1α KO and C57BL/6j WT control mice. The vertical line 
crossing each trace shows the time point of the light flash. +SEM of n=4. [C] Scotopic and [D] photopic b-
wave amplitudes from PGC-1α KO and C57BL/6 control mice as a function of the logarithm of the flash 
intensity. Boxes indicate the 25% and 75% quartile range, whiskers indicate the 5% and 95% quantiles. 
(c) Microarray analysis of PGC-1α KO and C57BL/6j WT control mice. Shown are the top 10 pathways up-
/downregulated in their mRNA expression of PGC-1α KO and C57BL/6j WT mice, dark exposed. n=3; * = 
p<0.05; ** = p< 0.01; *** = p<0.001. Statistical significance was calculated using ANOVA test, Benjamin 
Hochberg corrected. Thresholds for changes in gene expression set at 1.2 (20% above control) or 0.80 
(20% below control). 
 
 
Figure 3. Aberrant morphology and compromised function of PGC-1α KO mouse retina under light 
stress conditions. 
PGC-1α KO and C57BL/6j WT, aged 13 weeks, were exposed to 15.000 lux of white light for 2 hours and 
after 10 days of recovery subjected to morphological and functional analysis (a) Representative retinal 
morphologic sections from the lower central retina of PGC-1α KO and C57BL/6j WT mice. (b) [A] Scotopic 
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(dark-adapted) and [B] photopic (light-adapted) single-flash ERGs with increasing light intensities 
recorded from PGC-1α KO and C57BL/6j WT control mice. The vertical line crossing each trace shows the 
time point of the light flash. [C] Scotopic and [D] photopic b-wave amplitudes from PGC-1α KO and 
C57BL/6 control mice as a function of the logarithm of the flash intensity. (c) Optical coherence 
tomography (SD-OCT): [A] comparison of two representative OCT horizontal slices of PGC-1α KO and 
C57BL/6j WT control mice. [B] Magnification of these SD-OCT horizontal slices: left side: C57BL/6, right 
side: PGC-1α KO; GC= ganglion cell layer, IPL= inner plexiform layer, INL= inner nuclear layer, OPL= 
outer plexiform layer, ONL= outer nuclear layer, OLM= outer limiting membrane, IS/OS=inner segment/ 
outer segment, RPE= retinal pigment epithelium [C] Topography of retinal thickness of C57BL/6 (side) 
and PGC-1α KO (right) mice calculated from 61 equidistant SD-OCT slices (green= dense; blue= less 
dense). 
 
 
Figure 4. Microarray: Ablation of PGC-1α affects gene expression changes relative to apoptosis, 
inflammation, protein folding and phototransduction. Microarray analysis of light exposed PGC-1α KO 
and C57BL/6j WT control mice. +SEM for n=3 (a) number of genes changed significantly between 
genotypes and conditions: thickness of arrow relates to number of genes changed. (b) Heat map: 
expression patterns of a representative selection of genes involved in apoptosis, inflammation, DNA repair 
and phototransduction. Green= upregulated; red= downregulated; black= unchanged. (c) Semi-
quantitative real time PCR validation examples of pro apoptotic, anti apoptotic, inflammatory and 
phototransduction genes changed significantly in the microarray. 18SrRNA was used as HKG. P value 
was calculated using two tailed Student’s T test: * = p<0.05; ** =p<0.01. + SEM of n=3; Koli= PGC-1α 
knockout, light condition, Koda= PGC-1α KO, dark condition, Wtli= C57BL/6 WT, light conditions, Wtda= 
C57 BL/6 WT, dark condition. 
 
 
Figure 5. PGC-1α alleviates retinal apoptotic response upon light stress in vivo and in vitro. 
Relative quantification of cell death. P value was calculated using two tailed Student’s T test: *= p<0.05; ** 
= p< 0.01; ***= p<0.001  (a) PGC-1α KO and C57BL/6j WT mice were exposed to 15’000 lux of white light 
for 2 hrs. After 24hrs, retina was extracted and analyzed for free nucleosomes as a measure of cell death 
via ELISA. +SEM of n=11 (WT) and n=15 (PGC-1α KO). (b) Retinal pigment epithelial cells ARPE-19 
were transduced with adenovirus carrying GFP or mouse PGC-1α. Semi-quantitative real time PCR of 
PGC-1α and its targets Cox5b (cytochrome c oxidase subunit Vb) and (cytochrome c) in PGC-1α versus 
GFP transduced ARPE-19 cells. 18SrRNA was used as HKG. +SEM of n=6 (c) ARPE-19 cells were 
transduced with adenovirus carrying GFP or PGC-1α, treated with apoptosis inducers actinomycin D or 
camptothecin and then analyzed for cell death via immunostaining of released cytochrome c. ACT= 
Actinomycin D, CAMP= Campthothecin. 18SrRNA was used as HKG. +SEM of n=6. 
 
Figure 6. PGC-1α and PGC-1β are reduced in rd10 and VPP retinal degeneration models 
Retina from rd10 and VPP mice was isolated at different PNDs (postnatal days) and checked for 
expression of genes via semi- quantitative real time PCR. β-actin was used as HKG. +SEM of n=3 per 
time point. (a)-(c) rd10 mouse model: Rhodopsin (Rho) was used as control gene diminished in this 
condition. (d)-(f) VPP mouse model: Interleukin 1-β (Il-1β) was used as control gene marking the duration 
of the inflammatory response phase. (i) Loss of the PGC-1α gene in mice affects all the steps of the major 
cascade of events in light-induced retinal damage, repair and regeneration and consequently results in 
abnormal retinal morphology and function. 
 
Suppl. Fig1. Gene expression analysis of WT and PGC-1α KO mice in light and dark. (a) Microarray 
analysis of light and dark exposed PGC-1α KO and C57BL/6j WT control mice; Gene expression changes 
in the four comparisons: 18sRNA was used as HKG. +SEM for n=3; * = p<0.05; ** = p< 0.01; *** = 
p<0.001. Statistical significance was calculated using two tailed Student’s T test (b) phototransduction 
genes, (c) pro and anti apoptotic genes, (d) inflammatory genes and (e) PGC-1α and PGC-1β gene 
expression. 
 
Suppl. Table1. Microarray analysis of light and dark exposed PGC-1α KO and C57BL/6j WT control 
mice: top genes and pathways. (a) Top 10 genes most highly up-/downregulated in their mRNA 
expression of PGC-1α KO and C57BL/6j WT mice, dark vs light exposed. (b) Top 10 pathways up-
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/downregulated in their mRNA expression of PGC-1α KO and C57BL/6j WT mice, dark vs light exposed. 
n=3; * = p<0.05; ** = p< 0.01; *** = p<0.001. Statistical significance was calculated using ANOVA test, 
Benjamin Hochberg corrected. Thresholds for changes in gene expression set at 1.2 (0.2x upregulated) or 
0.87 (0.2x downregulated). 
 
Suppl. Table2. Microarray analysis of light and dark exposed PGC-1α KO and C57BL/6j WT control 
mice. significant changes in genes involved in apoptosis, DNA repair, inflammation and 
phototransduction. green= upregulated; red= downregulated (a) pro and anti-apoptotic, DNA repair genes 
(b) phototransduction and protein folding genes (c) ECM breakdown and inflammatory genes 
 
Suppl. Table3. List of primers used for semi- quantitative real time PCR  
 
 
Methods 
 
Animals 
 
All animal experiments were performed according to procedures approved by the veterinary authorities 
and according to the statement of “The Association for Research in Vision and Ophtalmology” for the use 
of animals in research. Wildtype C57 BL/6 NRj mice were purchased from Janvier (Le Genest St. Isle, 
France). C57 BL/6 PGC-1α global KO mice were a kind gift of Bruce M. Spiegelman, Dana- Farber 
Cancer Institute and Department of Cell Biology, Harvard Medical School (Boston, MA).  Rd10 (= retinal 
degeneration 10) mice were purchased from Jackson Lab (Bar Harbor, Maine). VPP (= mutant opsin 
transgene) mice were obtained from Muna Naash, University of Oklahoma (Oklahoma City, Oklahoma). 
Nrl (Neural retinal leucine zipper) KO mice were purchased from the University of Michigan (Ann Arbor, 
Michigan). Mice were maintained in a 12h : 12h light-dark cycle (60lux).  
 
Light exposure 
 
Six to thirteen- week old male C57 BL/6 PGC-1α global KO mice and wildtype C57 BL/6 NRj mice were 
dark adapted overnight (16hrs). Pupils were dilated with 1% cyclogyl (Alcon, Cham, Switzerland) and 5% 
phenylephrine (Ciba Vision, Niederwangen, Switzerland) for 45 min. before light exposure. Mice were 
exposed to 15’000 lux of light for two hours. Following overnight recovery in darkness, mice were 
analyzed at time points indicated in the results section. Mice that were dark adapted and not exposed to 
light served as controls. 
 
Morphology and cell death detection ELISA 
 
For morphology, eyes were fixed in 2.5% glutaraldehyde in 0.1M cacodylate buffer (pH 7.3) at 4°C 
overnight. The superior and inferior retinae were prepared, washed in cacodylate buffer, incubated in 
osmium tetroxide for 1 hour, dehydrated graded in alcohol series. Epon 812 sections (0.5µM) from the 
lower central retina were counter-stained with methylene blue.  
Cell death was quantified 24hours after light exposure in isolated retinas using the ELISA-based cell death 
detection kit (Roche Diagnostics, Mannheim, Germany). 
 
Laser capture microdissection  
 
Mice were sacrificed, eyes enucleated, embedded in tissue freezing medium (Leica Microsystems 
Nussloch, Germany) and frozen in 2-methylbutane bath cooled by liquid nitrogen. Retinal sections (20 µM) 
were fixed (5 min. acetone), air-dried (5 min.) and dehydrated (30sec 100% ethanol, 5 min. xylene). 
Microdissection was performed using an Arcturus XT Lasercapture device (Molecular devices, Silicon 
Valley, CA).  
  
Gene Expression Studies 
 
RNA was isolated by pooling 2 retinas from 1 animal using the miRNeasy Mini Kit from Qiagen. 1μg of 
RNA was employed for cDNA synthesis using Super Script Reverse Transcriptase II (Invitrogen) and 
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random hexamer primers (Promega, Madison, USA). Real-time PCR analysis (Power SYBR Green 
Master Mix, Applied Biosystems, Carlsbad, California, USA) was performed either by using the 
LightCycler 480 Sybr Green I Master Kit and a LightCycler 480 instrument (Roche, Mannheim, Germany) 
or by Power SYBR Green Master Mix using the StepOnePlus sequence detector (Applied Biosystems, 
Carlsbad, California, USA). Relative expression levels were calculated with the ΔΔCt method and 
normalized to the expression of β-actin or 18S ribosomal RNA (18SrRNA) with primers indicated in 
Suppl.Table3. 
 
Cell culture and adenoviral infection  
 
ARPE-19 cells were seeded at 2x10E5 cells per well of a 12 well plate in 50% F-12/ 50% DMEM medium 
supplemented with 1% Penicillin/ Streptomycin. 24h afterward, cells were infected with adenoviral 
constructs encoding GFP and PGC-1α, respectively. 
 
Apoptosis induction and cell death detection 
 
48h after adenoviral infection, cells were treated with Z-VAD-FMK (Peptanova, Sandhausen, Germany) for 
60min to prevent cell detachment. Apoptosis inducers Camptothecin or Actinomycin D (final concentration: 
20μM) were added. 24h later, cells were fixed with 4% paraformaldehyde in PBS, washed with PBS and 
stained with anti-cytochrome c (BD biosciences). Released cytochrome c was quantified using 
fluorescence microscopy. 
 
ERG measurements 
 
Electroretinograms (ERGs) were recorded according to previously described procedures
136
. Mice that 
were light exposed as described above were analyzed 10 days after light damage. Non-exposed mice 
served as controls. All mice were dark- adapted overnight prior to ERG analysis. Mice were then 
anaesthetized with ketamine (66.7 mg/kg body weight) and xylazine (11.7 mg/kg body weight). Pupils 
were dilated and single flash ERG responses were obtained under dark-adapted (scotopic) and light-
adapted (photopic) conditions. Light adaptation was accomplished with a background illumination of 30 
candela (cd) per square meter starting 10 min before recording. Single white-flash stimulus intensity 
ranged from –4 to 1.5 log cd s/m2 under scotopic and from –2 to 1.5 log cd s/m2 under photopic 
conditions.  
 
Spectral domain optical coherence tomography (SD-OCT) 
 
Eyes were subjected to SD-OCT using the commercially available Spectralis™ HRA+OCT device from 
Heidelberg Engineering featuring a broadband superluminescent diode at λ = 870 nm as low coherent 
light source
137
. 
 
Gene expression profiling 
 
RNA was isolated as described above (Gene expression studies) and 4.25ug of cDNA from the mouse 
retinae was hybridized to the Affymetrix Gene Chip Mouse 1.0 ST at the in-house microarray facility 
service. Microarray CEL output files were analyzed at the Functional Genomics Center Zurich, 
Winterthurerstrasse 190, CH-8057 Zurich. Statistical significance was calculated using ANOVA test, 
Benjamin Hochberg corrected. Thresholds for changes in gene expression set at 1.2 (0.2x upregulated) or 
0.87 (0.2x downregulated). p ≤ 0.05 = *, p ≤ 0.01 = **, p ≤ 0.001 = ***. 
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4.4.  Conclusions 
 
In this study, the coactivator PGC-1α was found to occupy a crucial role in retinal health:   
Whereas it is dispensable for retinal morphology and function in an unstressed, dark exposed condition, 
high intensity light exposure leads to enhanced apoptosis and decreased DNA repair in the absence of 
PGC-1α. However, it cannot be concluded from these data whether the coactivator delivers the additional 
energy required for recovery and DNA repair after a light insult or if PGC-1α directly steers transcription of 
genes involved in recovery and DNA repair. 
 
The ERG data also confirm that ablation of PGC-1α in the light treated animals accounts for compromised 
phototransduction. In fact, the ERG response of the KO animals was quite variable: This may be due to 
the process of light exposure where animals can receive unequal amounts of light in accordance with the 
movements that they make. Furthermore, the ERG is a good device to detect sound functional 
abnormalities in retina, whereas retinal damage that is restricted to certain areas may not always be 
detected via an altered Ganzfeld ERG. A longer light exposure could have helped alleviate this problem.  
 
The role of PGC-1α in retinal development was also investigated: 
Lifelong absence of PGC-1α does not seem to affect morphology at a later stage in life: 10 month old and 
3.5 month old PGC-1α KO animals do not differ in retinal morphology from the respective WT controls in 
their amount and distribution of SWL and MWL cone opsins. (Fig. 8A). SWL seems to be distributed 
preferentially in the ventral region in the KO and WT animals of 3.5 and 10 months; MWL on the other 
hand is distributed equally in the dorsal and ventral region in KO and WT animals (Fig. 8B) (Data: 
courtesy of Marijana Samardzija). 
Likewise, some important genes involved in retinal function are not markedly changed in their expression 
between PGC-1α KO and WT mice in a timecourse experiment (Fig.9). 
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(A)               (B) 
 
Fig.8: Morphological analysis of 3.5 and 10 month old PGC-1α KO and WT animals 
Immunofluorescence staining of mouse retina: blue: DAPI staining, red= opsin staining; 10m= 10 month old animals, 
3.5m= 3.5 month old animals (A) retinal sections: SWL= short wave length cone opsin; MWL= mid wave length cone 
opsin. COS= cone outer segments, ONL= outer nuclear layer, INL= inner nuclear layer, GCL= ganglion cell layer (B) 
retinal panorama: dorso- ventral orientation. D= dorsal, V= ventral 
courtesy of Marijana Samardzija. 
 
       
     
Fig.9: Gene expression in PGC-1α KO and WT mouse retina at different ages. Day5 – Day60. Expression of 
retinal genes measured by semi-quantitative real time PCR. Normalization against 5day old WT mouse 
retina.18SrRNA was used as housekeeping gene. n=2. +SEM 
 
On balance, PGC-1α protects murine retina from high intensity light induced damage to photoreceptors. 
WT           PGC-1α KO PGC-1α KO          WT 
 
V V D D 
D V V D 
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5.  The role of PGC-1β in skeletal muscle 
 
5.1. Introduction 
 
Most research efforts thus far have focused on elucidating the role of PGC-1α in different tissues. PGC-
1β, the closely related isoform of PGC-1α, has not been studied to that extent: First identified in BAT, 
PGC-1β coactivates most of the transcription factors also targeted by PGC-1α involved in OXPHOS such 
as NRF-1, ERRα and PPARα
39,138
. Like PGC-1α, it is also expressed in heart, skeletal muscle, liver and 
pancreatic islets
139,140,141,142
. Still, it also exhibits non redundant coactivation functions:  
In liver, it regulates hepatic lipogenesis as well as lipoprotein secretion by coactivating sterol regulatory 
element binding protein 1c, 1a (SREBP1c, SREBP1a) and forkhead transcription factor A2 (FOXA2)
141,143
. 
Upon induction by dietary fats, PGC-1β causes a shift of triglycerides and very low density lipoprotein 
(VLDL) from the liver to the blood by coactivating FOXA2.  
PGC-1β seems to be implicated in glucose homeostasis by reversing hepatic insulin resistance caused by 
fructose
144
. 
 
5.1.1. PGC-1β in skeletal muscle 
 
The role of PGC-1β in skeletal muscle has not been defined that clearly. Most information can be 
gathered from global KO and skeletal muscle specific overexpression mouse models of PGC-1β: Yet, as 
PGC-1 is differentially expressed with regard to the tissue (e.g. low expression in liver vs high expression 
in skeletal muscle) and is strongly associated with the metabolic status (e.g. fed vs fasted conditions) and 
health status, the global KO models have to be assessed with caution (Table1): 
PGC-1β manipulation models 
manipulation phenotype 
Systemic ablation 
145
 
Impaired mitochondrial function, reduced body weight and fat mass, increased thermogenesis, 
blunted chronotropic response to dobutamine in the heart, HFF leads to hepatic steatosis and 
reduced plasma triglycerides and cholesterol 
Systemic ablation 
139
 
Decreased activity in the dark cycle, abnormal hypothermia and morbidity when exposed to cold, HFF 
leads to hepatic steatosis, increased serum triglyceride and cholesterol 
Systemic deletion 
of exons 3-4, 
hypomorphic
146
 
Mitochondrial dysfunction in liver and skeletal muscle but hepatic insulin resistance, elevated liver 
triglycerides in the fed state 
Skeletal muscle 
specific 
overexpression 
140,
 
147
 
Increased fatty-acid oxidation, hyperphagia, reduced body weight and adipose tissue, increased 
exercise capacity,  increased angiogenesis, increased IIX fiber content 
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Skeletal muscle 
specific 
overexpression
148
 
Amelioration of insulin resistance in rats fed a high fat diet, decreased level of long chain acyl CoAs, 
increased antioxidant defense 
Liver and adipose 
tissue specific 
Knockdown 
144
 
Reversal of hepatic insulin resistance caused by fructose, reduction of SREBP expression , increase 
of whole body insulin stimulated glucose disposal, increased uptake of glucose into adipose tissue 
Liver specific 
overexpression 
149
 
Hyperlipidemia, increased hepatic triglyceride secretion, SREBP levels unchanged, on HFD decrease 
of SREBP 1c and plasma triglyceride levels 
Skeletal muscle 
specific KO
150
 
Decreased exercise performance, decreased expression of genes implicated in OXPHOS, regular 
glucose tolerance and insulin sensitivity 
 
Table1: Tissue specific and systemic manipulation models of PGC-1β 
Adapted from
79
. 
 
In an unstressed setting, the PGC-1β global KO mice are viable, fertile, but display signs of activity 
reduction
139,145
. Upon cold exposure, they develop hypothermia
139
. 
All three global PGC-1β KO/ hypomorphic models display reduced expression of OXPHOS genes in 
skeletal muscle (soleus)
145,139,146
. Mitochondrial volume and function in soleus is decreased in two 
models
145,146
. Interestingly, despite hepatic insulin resistance upon high fat diet (HFD), skeletal muscle of 
the hypomorphic animals responds to insulin like the control animals
146
. 
HFD leads to changes in plasma triglycerides and cholesterol: Both Sonoda et al and Lelliott et al reported 
hepatic steatosis in their KO animals compared to the WT animals upon HFD. However, Lelliott et al 
witnessed decreased plasma triglyceride and cholesterol levels in the HFD KO animals compared to 
controls whereas Sonoda described them as increased
139,145
.  
 
Overexpression of PGC-1β in skeletal muscle decreases body weight and adipose tissue and increases 
exercise capacity. A second skeletal muscle specific overexpression model was published during the 
course of this project (see discussion part).    
 
A skeletal muscle specific knockout model of PGC-1β was also published during the course of this project 
by Zechner et al
150
 (see discussion part). 
 
5.1.1.1. PGC-1β and angiogenesis 
 
A skeletal muscle specific PGC-1β overexpression model has helped to explain its tissue specific function: 
It induces OXPHOS and mitochondrial biogenesis and it also stimulates angiogenesis via VEGF 
induction
147
. 
 
 
 - 54 - 
5.1.1.2. PGC-1β and fiber type determination 
 
Like PGC-1α, PGC-1β is involved in fiber type determination: It causes a strong induction of IIX fibers. IIX 
fibers are oxidative but have “fast-twitch” biophysical properties and thus constitute intermediates between 
IIA and IIB fibers. They are transiently recruited during fiber type conversion from IIB to IIA
151
 and their 
frequency increases with age
152
. At the same time, type I and IIA MHC expression are repressed by PGC-
1β. This inverse correlation between PGC-1β levels and percentage of type I fibers was also observed by 
Mortensen et al
153
: They could show that endurance training lowers PGC-1β expression levels. Strikingly, 
in transgenic PGC-1β mice, every fiber in the observed skeletal muscle types is oxidative and the mice 
can run longer than WT animals. The question arises if this is due to an increase in type IIX fibers.  
 
5.1.1.3. Specific role of PGC-1β in skeletal muscle 
 
PGC-1α and PGC-1β display different regulation patterns in response to physiological stimuli: While PGC-
1α is clearly increased/ decreased upon exercise/ obesity in skeletal muscle, PGC-1β is not altered upon 
exercise
154
.  
This finding raises the question if PGC-1β fulfills a specific task in skeletal muscle different from PGC-1α.  
 
5.1.1.4. PGC-1β and glucose homeostasis 
 
PGC-1α is implicated in efficient glucose uptake and utilization via induction of GLUT4 transporter 
expression
5
.  
 
It is a well - known observation that PGC-1α and PGC-1β are decreased in skeletal muscle from patients 
with type II diabetes whereas PGC-1α is increased in type II diabetes models in liver
84,7
. This drop in 
PGC-1 levels may lead to a reduced expression of NRF dependent genes, which is characteristic of 
insulin resistance
84
. A skeletal muscle specific KO of PGC-1α leaves peripheral insulin sensitivity 
unchanged yet impairs glucose tolerance compared to WT animals
13
.  
 
Yet, it is not known how skeletal muscle specific KO animals for PGC-1β handle glucose uptake. 
Furthermore, the two coactivators have different regulatory functions on glucose and fat metabolism in 
skeletal muscle: Whereas expression of PGC-1α in muscle is positively related to glucose uptake and 
oxidation, PGC-1β expression correlates with non-oxidative glucose metabolism
155
. 
 
It would be interesting to know if a combined reduction of PGC-1α and β is required for overt insulin 
resistance in skeletal muscle.  
 
 - 55 - 
Three questions must thus be answered: How does PGC-1β affect fiber type composition? What are the 
exclusive targets of PGC-1β in skeletal muscle? How is PGC-1β implicated in glucose homeostasis in 
skeletal muscle? 
We therefore conceived a strategy that should allow for temporary reduction of PGC-1β specifically in 
skeletal muscle.   
 
5.1.2. Skeletal muscle specific knockdown of PGC-1β  
 
5.1.2.1. The construct 
 
Over the last decades, a wide array of nucleic acid based constructs for sequence specific gene regulation 
has been developed: However, none of these has sparked more interest than RNA interference (RNAi):  
 
Initially described in the nematode Caenorhabditis elegans
156
, RNAi comprises microRNA (miRNA) and 
small interfering RNA (siRNA) mechanisms:  
miRNA is a system of endogenous gene regulation in multicellular eukaryotes that inactivates mRNA. Pri-
miRNA constructs consist of 2 imperfectly base paired RNA strands connected via a loop structure that is 
transcribed by Polymerase II in the nucleus. Upon cleavage with Drosha, the resulting pre-miRNA is 
released from the nucleus in an exportin-5 dependent fashion, processed by Dicer which yields miRNA. 
This miRNA is then incorporated into a complex containing an RNA induced silencing complex (RISC) and 
Argonaute protein2 (AGO2) which recognizes target sites at the 3’ untranslated region (UTR) of mRNAs 
and leads to translational inhibition and mRNA degradation
157
.  
siRNAs were first discovered in plants as eukaryotic defense system against viruses
158
. They consist of 
double stranded RNAs of around 21BPs size with 2 nucleotides overhang at their 3’ ends. They are 
perfectly complementary to their mRNA target and reduce mRNA levels by mimicking miRNA leading to 
mRNA cleavage.  
shRNAs are exogenous, imperfectly base paired double stranded RNAs that mimic pre-miRNA leading to 
mRNA degradation. They contain a base paired stem, loop and a 3’ terminal UU overhang.  
shRNA-mir is a further development of shRNAs which mimics pri-miRNA.  
 
As both shRNA-mir and shRNA enter the silencing cascade far more upstream than siRNA and are 
usually delivered via vectors, they allow for long-term, stabler knockdown than would be possible with 
siRNA
159,160
.  
We therefore strived for the generation of a shRNA-mir based vector to knock down PGC-1β.  
 
One important caveat in dealing with shRNA is its potential toxicity: If shRNA expression is too high, the 
endogenous exportin-5 system is oversaturated and shRNA delivery, especially in vivo, can be toxic or 
fatal
161
. This limitation can be overcome by employing polymerase II promoters which are used by the cell 
 - 56 - 
to generate miRNA: In contrast to the ubiquitously expressed, potent polymerase III promoters (U6, H1), 
polymerase II promoters are often tissue specific and grant more attenuated gene expression
159
.  
 
Fig.10: RNAi: Exogenous shRNA and siRNA versus endogenous miRNA pathways 
adapted from
162
 
 
5.1.2.2. The delivery 
 
5.1.2.2.1. Somatic delivery 
 
One possible avenue of administering the shRNA construct is systemic (intraperitoneal or intravenous 
injection): This necessitates the use of skeletal muscle specific promoters to avoid expression of the 
construct throughout the body. Furthermore, this approach has two major limitations: First, the shRNA 
may easily be degraded and diluted upon injection. Second, for efficient knockdown, the shRNA needs to 
be injected repeatedly. This technique thus lends itself more to being a complementary approach, for 
example in tumor treatment
163
. 
 
5.1.2.2.2. Transgenic mouse delivery 
 
Tissue specific KO models have paved the way for studying the organ specific function of genes and 
enabling the generation of animal models that would not thrive were the protein globally ablated. Typically, 
these models also avail themselves of inducible KO (e.g. tetracycline or tamoxifen controlled) which 
avoids interference with developmental programs that would further hamper the analysis of the gene of 
interest
164
.  
shRNA-mir 
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This technique can be combined with delivery of shRNA: Gao et al published the generation of a 
transgenic RNAi mouse where the shRNA construct is driven by a H1 promoter. This construct is then 
injected into the pronuclei of mouse one-cell embryos
165
. This technique was also used for creating an 
inducible KO by Dickins et al: They bred transgenic mice harboring a tetracycline responsive RNA 
polymerase II promoter driving a shRNA targeting p53. Upon crossing with mouse strains expressing 
tissue specific or general transactivator proteins that can be either activated (tet-on) or repressed (tet-off) 
by tetracycline, transient expression of shRNA is achieved
166
. 
 
5.1.2.2.3. Viral delivery 
 
We strived for a system, which is potentially more time saving and cost effective than the ones mentioned 
above:  
Jointly with stem cell therapy, gene therapy has emerged as a tool for combating acquired or hereditary 
diseases during the last decades: The generation of a virus harboring the therapeutic gene, its 
propagation, delivery to the host and ultimately expression has been achieved using a tailored virus 
attenuated in its original properties (for recent review see
167
): Three viral strains, namely adenovirus (AV), 
adeno-associated Virus (AAV) as well as lentivirus (LV) have been tested in animal models and are 
starting to be successfully used in clinical trials (e.g.:
168
, Amsterdam Molecular Therapeutics: Glybera). 
Their route of viral delivery can be local or systemic. The present hurdles of gene therapy are mostly host 
inflammatory responses as well as transduction problems.  
As AAV and LV both appeared to be interesting candidates for our approach we scrutinized their potential 
for our project (table2). We eventually opted for the use of AAV:  
AAV belongs to the family of parvoviridae and is a single stranded DNA virus. It infects preferentially 
postmitotic, quiescent cells. In most cases, it does not integrate into the genome but remains episomal 
and does not lead to pronounced immune response. Furthermore, the wildtype virus is replication – 
deficient and thus requires a helper AV to replicate itself, making it a safe tool for gene therapy. 
Structurally, AAV has an icosahedral capsid that can accommodate about 5kB of foreign DNA. The AA 
virion consists of two large open reading frames (ORFs) that encode for the replication (rep) and capsid 
(cap) proteins VP1, VP2 and VP3 controlled by a p40 promoter. Both sides of the genome are flanked by 
inverted terminal repeats (ITRs) responsible for AAV genome replication
169
.  
AAV life cycle starts with binding to cellular surface receptors like heparin sulfate proteoglycan (HSPG), 
fibroblast growth factor receptor-1 (FGFR1), integrin αvβ5 and hepatocyte growth factor receptor (HGRF) 
and subsequent internalization via clathrin-mediated endocytosis. Second, the AAV is channeled to the 
nucleus, where it is uncoated and the vector genome is released. This vector genome then has to be 
completed from single stranded to double stranded DNA to serve as a template for transcription. This very 
process is the rate limiting step in the use of AAV for gene therapy: It can thus take up to several weeks 
until the second strand of the genome is successfully synthesized. Another bottleneck is the number of 
cellular surface receptors that can vary according to the tissue/ cell type used
170
. 
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The standard manufacturing approach of AAV is achieved through triple transfection of three vectors: first, 
the vector containing the genome plus the transgene flanked by two internal repeats (ITRs), second a 
helper plasmid that provides replication (rep) and capsid (cap) proteins and third, a helper plasmid of 
adenoviral origin containing the essential early genes E1, E2A, E4 in cell culture
171
. 72hrs post 
transfection, the AA virions can be harvested from the cell lysate
167
.  
 
There were two major features of AAV that made us opt for this approach: 
 
First, contrary to LV and AV, AAV displays considerable tissue tropism: 11 different serotypes have been 
characterized. These serotypes distinguish themselves from one another mainly by their capsid proteins 
which determine tissue tropsim allowing for targeted uptake of the virus into various tissues 
(photoreceptors and retinal pigment epithelial cells, skeletal muscle, cardiac muscle and liver cells
172
 - see 
table3). This feature would allow for targeted uptake of AAV into skeletal muscle irrespective of the route 
of delivery (systemic or local injection) using AAV6: AAV6
173
 has a strong tropism for skeletal muscle, 
albeit also cardiac muscle
174,175
 where it has been used for treating severe heart failure
167
. AAV2 displays 
a broad tissue tropism and has been used in clinical trials with muscular, subretinal and intracranial 
administration
167
. It is also the most widely studied and best characterized serotype. However, AAV2 
displays a slower onset of protein expression (28 days postinjection) from the gene of interest delivered 
than does AAV6 (7 days postinjection)
174
. We thus tried to combine AAV2 with the capsid from AAV6, 
generating a so called pseudotyped AAV2/6 that harbors the genetic properties of AAV2 whilst displaying 
tissue tropism of AAV6. 
Second, up to now, infection with AAV has not been associated with considerable immune response. It 
can, however, lead to some cellular and humoral immune response which engenders neutralizing 
antibodies. This phenomenon is observed when AAV from the same serotype is administered 
repeatedly
176
. As both PGC-1α and PGC-1β are downregulated in disease states that comprise low level, 
systemic inflammation
84
 and they counter inflammatory response
72
 , we sought for a model that does not 
trigger immune system activation.  
However, there are also downsides to the use of AAV: it does not lend itself to the production of high titer 
virions. Also, transduction efficiency in culture for diverse cell types is more efficient in AV and LV (table 
2). Finally, the scaling up of AAV production is also not as straightforward as with AV
177
. 
 
 AV AAV LV 
Insert size 7.5kB 5.0kB 8.5kB 
Inflammatory response high low Medium to high 
Host genome integration no no possible 
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Transduction efficiency All cell types nearly 
100% 
Dividing and non- 
dividing cells; tropism 
is serotype specific 
Dividing and non- dividing 
cells 
High level of protein 
expression 
yes no no 
Easy to scale up in 
production 
yes no no 
Easy to get high titers > 
1x10E9 
yes no no 
 
Table2: properties of AV, AAV and LV: adapted from http://signagen.com/ 
 
 
 
Table3: AAV serotypes and their tissue tropism:
171
 
 
We finally decided to opt for AAV mediated knockdown of PGC-1β in skeletal muscle.  
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5.2. Project aims 
 
Before the project start, only global or liver specific KO models as well as skeletal muscle specific 
overexpression models have been used to explain the roles of PGC-1β in skeletal muscle. As seen for 
PGC-1α, expression of PGC-1β is tissue specific and systemic effects in global KO animals often hamper 
analysis of gene function in specific tissues
13,112
. Thus, in order to specifically assess the function of PGC-
1β in skeletal muscle, it is crucial to limit PGC-1β ablation to this tissue.  
 
Therefore, the involvement of PGC-1β in glucose homeostasis and fiber type determination was answered 
in generating a skeletal muscle specific PGC-1β knockdown (KD) model using RNAi directed against 
PGC-1β. KD rather than KO allows for a moderate to pronounced downregulation of PGC-1β rather than 
complete ablation. Delivery of the KD construct was done via systemic and local injections of AAV carrying 
the KD sequence against PGC-1β. After testing KD efficiency via qPCR and Western Blot, systemic tests 
should be carried out to unveil the effects of PGC-1β reduction on glucose homeostasis. Skeletal muscle 
fiber type should be characterized via fiber staining.  
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5.3. Material and Methods 
 
 
Design and cloning of shRNAs to knock down PGC-1β 
 
Three different design modi (construct1, construct2, construct3- see results section) were used to 
generate shRNA-mir against mus musculus PGC-1β (Genbank accession number NM_133249):  
All shRNA-mir constructs are hereafter designated as shRNA for simplicity. 
The sequences were subjected to BLAST analysis http://blast.ncbi.nlm.nih.gov/Blast.cgi to ascertain if 
they were specific for PGC-1β.  
Subsequently, constructs were cloned into pU6-mir30, pMan, pcDNA3.1(+), pAAV-CMV-MCS and pAAV-
CK6-MCS backbones, respectively, using Vector NTI 7.0 (Invitrogen, Carlsbad, California) and Geneious 
(Geneious, Auckland, New Zealand) softwares. Backbone pSuper already contained the shRNA.   
Cloning was carried out according to the handbook “Molecular Cloning: A Laboratory Manual”, Third 
Edition, Sambrook and Russell, Cold Spring Harbor Laboratory Press, 2001.  
Owing to the size of the shRNA constructs (around 70BPs), the shRNAs were ordered as single stranded 
oligos containing the necessary restriction sites, annealed and inserted into the plasmids containing the 
shRNA flanking sequences: 
shRNA2 and scrashRNA were cloned in pU6-mir30 using the restriction sites XhoI and EcoRI. 
shRNA3 was cloned into pMan using the restriction sites for MfeI. 
shRNA4 was already contained in the pSuper backbone. 
shRNA2 - pU6mir-30 flanking sequence and scrashRNA-pU6mir-30 flanking sequence were cloned into 
pcDNA3.1(+) via a HindIII restriction site. 
shRNA4 of pSuper was also cloned into pcDNA3.1(+) via a HindIII restriction site. 
shRNA2 – pU6mir-30 flanking sequence and scrashRNA – pU6mir-30 were inserted into pAAV-CMV 
using the HindIII restriction site. 
GFP was cloned into pAAV- CMV- shRNA2pU6mir via BglII restriction sites. 
shRNA2 - pU6mir-30 flanking sequence and scrashRNA-pU6mir-30 flanking sequence were cloned into 
pAAV-CK6 via SacI and BsmI restriction sites. 
 
Cell lines and respective culture conditions 
 
HEK293 cells were cultivated at 37°C in 5% CO2. DMEM (high glucose) (Gibco, Invitrogen, Carlsbad, 
California, order no 10313-039:) supplemented with 10% FBS (Gibco, Invitrogen, Carlsbad, California, 
order no 10099158), 1% Penicillin/ Streptomycin (Gibco, Invitrogen, Carlsbad, California, order no 15070-
063) was used as medium.  
Sol8 and C2C12 cells were cultivated similarly to HEK293 cells but 20% FBS was used for Sol8 cell 
cultivation.  
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Differentation of C2C12 and Sol8 cells 
 
C2C12 and Sol8 cells were grown to 90% confluency and then differentiated using regular cultivation 
medium containing 2% horse serum (Invitrogen, Carlsbad, California, order no 16050114). Medium was 
changed every 3
rd
 day. 
 
Skeletal muscle primary cells and respective culture conditions 
 
Primary cells from C57 BL/6 mouse skeletal muscle were cultivated in 79% F10 (Gibco, Invitrogen, 
Carlsbad, California, order no 11550-043) , 20% FBS hyclone (Hyclone Logan, Utah, order no HY-ME-
SH30070-02), 1% Penicillin/Streptomycin, 0.1% Fungizone (Invitrogen, Carlsbad, California, order no 
15290-018) and 0.01% bFGF (Invitrogen, Carlsbad, California, order no 13256-029). 
 
Differentiation of skeletal muscle primary cells 
 
 
Skeletal muscle primary cells were grown to 90% confluency and then differentiated using regular 
cultivation media with 5% horse serum. 
 
Cell line transfections 
 
HEK293 cells were split to 1x10E10 cells per 10cm diameter plate; 12 hours later cells were transfected 
with plasmids. Plasmids carrying shRNA sequences and control plasmid carrying FLAG tagged mouse 
PGC-1β were added to the cells in a molar ratio of 5:1. Calcium Chloride and HBS were used as 
transfection reagents according to “Der Experimentator: Molekularbiologie/Genomics”, Cornel Mülhardt, 
Elsevier GmbH, Fifth edition, 2006.  
 
Preparation of cell lysates 
 
48 hours post transfection, cells were harvested and protein was extracted in lysis buffer (10% glycerol, 
20mM Tris pH=8, 137mM NaCl, 1% Nonidet P-40, 1mM PMSF, 1x Protease inhibitor mix: Roche 
Diganostics, Mannheim, Germany, order no 11697498001). Cells were incubated in lysis buffer (300ul of 
lysis buffer per 1 Mio cells) for 30min. on ice and subsequently centrifuged. The resulting supernatant was 
frozen at -80°C. 
 
Western Blot  
 
Protein concentration of total protein extracts was analyzed via Bradford assay using bovine serum 
albumin as a standard (Bradford M et al, 1976). 
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50-100ug of protein was applied to a polyacrylamide gel and blotted onto PVDF membranes by semi-dry 
electroblotting (Thermo Scientific, Waltham, Massachusetts, order no OWHEP1). Membranes were 
stained with Ponceau S to verify equal protein amount per lane. After blocking (1% non fat milk powder, 
0.1% Tween 20 in Tris-buffered saline), blots were probed overnight with anti-FLAG antibody (Sigma 
Aldrich, St.Louis, Missouri, order no F3165) or anti α- tubulin (Cell Signaling, Danvers, Massachusetts, 
order no 2125) using dilutions 1:2000 and 1:1000, respectively. Detection was carried out using 
horseraddish peroxidase conjugated anti mouse (GE Healthcare, Waukesha, Wisconsin, order no NA931) 
and anti rabbit (Jackson Immuno Research, West Grove, Piscataway, oder no 111-035-144) antibodies. 
ECL Dura (Thermo Scientific, Waltham, Massachusetts, order no 34075) was used for protein 
visualization. 
 
AAV production 
 
AAV was produced in three ways: using a commercially available kit, ordering AAV from an industrial 
production facility and from a university based AAV production facility. 
 
Commercially available kit 
AAV Helper Free System (Agilent, Santa Clara, California, order no 240071) was used to produce AAV: 
AAV2 was produced via triple transfection of AAV293 cells with pAAV-CMV-shRNA2/ pAAV-CMV-
scrashRNA/ pAAV-GFP-IRES, pHelper and pAAV-RC according to the protocol guidelines. 20x 10mm 
diameter cell culture plates were used per construct. Virus was aliquoted and stored at -80°C.  
Virus purification was done using Fast Trap- Adeno Associated Virus Purification and Concentration Kit 
(Millipore, Billerica, Massachusetts, order no FTAA 000 03). 
Virus titration was carried out using the QuickTiter™ AAV Quantitation Kit (Cell Biolabs, San Diego, 
California, order no VPK-145) and AAV2/3 titration ELISA (Progen Biotechnik GmbH, Germany, order no 
PRATV).  
 
AAV production facility 
pAAV-GFP-IRES,  pAAV-CMV-shRNA2, pAAV-CMV-scrashRNA and pAAV-CMV-shRNA2-GFP were 
sent to “Institut de Recherche Thérapeutique, Université de Nantes – INSERM U649” for production and 
titration of AAV2/6. 
 
University based AAV production facility 
pAAV-CK6-shRNA2 and pAAV-CK6-scrashRNA were used to produce and titrate AAV2/6 at “Baker Heart 
and Diabetes Institute (Baker IDI)”, Melbourne, Victoria according to the facility’s protocol: AD293 cells 
were triple transfected with pHelper, pCap6 and pAAV-CK6-shRNA2pU6/ scrashRNApU6 constructs. 
Upon virus harvesting three days posttransfection, the virus was concentrated in a HiTrap heparin column 
(GE Healthcare, UK) using high pressure liquid chromatography (HPLC) in a preparative Aekta purifier 
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(GE Healthcare, UK) and sucrose density gradient ultracentrifugation. Virus titration using semi-
quantitative real time PCR was followed by virus storage at -80°C. 
 
AAV2 transduction of cell lines and skeletal muscle primary cells 
 
Skeletal muscle cell lines C2C12, Sol8 and kidney cell line HEK293, respectively, were transduced with 
AAV2 in concentration ranges from 1x10E4- 1x10E7 vector genomes per cell by adding the virus directly 
to the cell culture medium. For this purpose, 80.000 cells were split per well of a 12 well plate 14hrs prior 
to transduction. 48hrs posttransduction, cells were analyzed.   
Differentiated C2C12 and skeletal muscle primary cells were cultivated for 3 days using differentiation 
medium and subsequently transduced with AAV2 virus particles. 
 
Mice 
 
C57 BL/6 JRj WT mice used for injections were purchased from Janvier, Le Genest St. Isle, France. 
 
 
AAV2/6 injections into tibialis anterior (TA) muscle 
 
C57 BL/6 JRj WT mouse TA was injected with AAV2/6-GFP-IRES, AAV2/6-CMV-shRNA2 , AAV2/6-CMV-
scrashRNA, AAV2/6-CK6-shRNA2, AAV2/6-CK6-scrashRNA or PBS as control: Two different 
concentrations, 1x10E10 vector genomes (VG) and 5x10E9 VG were used. Virus was diluted in PBS to a 
total volume of 40ul.  
TA muscle was extracted 7, 14, 21 and 28 days postinjection.  
TA was prepared for protein or RNA analysis (snap frozen in liquid nitrogen and stored at -80°C) or used 
for cryosections. 
 
Cryosections 
 
TA was embedded in a carrier (7% gum tragacanth in AD) that was fixed on a cork plate support by 
dripping it in cooled isopentane amylalcohol for 20 seconds. TA was stored at -80°C prior to preparing 12 
µm thick slices with a cryostat device (Microm HM 560, Thermo Scientifc, Massachusetts) and fixing them 
on superfrost slides (Menzel Gläser, Braunschweig, Germany, order no AA00008032E) Slides were air 
dried for 30 min. at room temperature and subsequently stored at -20°C. 
 
Immunofluorescence 
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Cryosection slides were fixed in 4% PFA (Sigma Aldrich, St. Louis, Missouri, order no 76240) in PBS for 
10min., washed 3x with PBS in individual glass chambers. Slides were then incubated with blocking 
solution made up of 2% BSA (Sigma Aldrich, St. Louis, Missouri, order no A9418) , 0.2% Triton-X ( Sigma 
Aldrich, St. Louis, Missouri, order no 93426, in PBS) for 30min., then incubated with the primary antibody 
for 1 hour, washed 3x with PBS, incubated with the secondary antibody for 1 hour in the dark. Slides were 
mounted with a coverslip using vectashield (Vector Labs, Southfield, Missouri, order no H-1400) and 
sealed with nailpolish. Slides were stored at 4°C protected from light until analysis. Confocal microscopy 
was done on a  Leica TCS-NT-SP1 (Leica instruments, Wetzlar, Germany). 
Primary antibodies used were anti mouse CD3 (1:400 dilution) (Abd Serotech, Kidlington, UK, order no 
MCA500GA) and CD68 (1:400 dilution) (Abd Serotech, Kidlington, UK, order no MCA1957GA). Secondary 
antibody used was goat anti rat IgG Alexa Fluor 488 (dilution 1:1000) (Invitrogen, Carlsbad, California, 
order no A11006). 
  
Hematoxylin and eosin staining 
 
For hematoxylin and eosin (H&E) staining, cryosection slides were incubated in 1%PFA in PBS for 15min., 
rinsed in H2O2 for 2x2min. and subsequently stained in Mayer’s hematoxylin solution (Sigma Aldrich, St. 
Louis, Missouri, order no MHS16) for 15min. Rinsing in 0.1% HCl for 30sec. was followed by washing in 
warm tap water for 15min. and then in AD for 30sec. Subsequently, slides were stained in Eosin Y (Sigma 
Aldrich, St. Louis, Missouri, order no HT110216) for 3min., rinsed with warm tap water for 30sec., 
dehydrated in 95% EtOH, 100% EtOH (Sigma Aldrich, St. Louis, Missouri, order no 02860) and Xylol 
(Merck, Whitehouse Station, New Yersey, order no 108681) (2x2min. each) and finally mounted with 
anhydrous mounting medium.    
 
Semi quantitative real time PCR 
 
RNA was isolated using the miRNeasy Mini kit from Qiagen (Qiagen, Venlo, Netherlands, order no 
74104). 
Tissue preparation:  
Up to 40mg of frozen TA muscle was homogenized in 700µl of Qiazol.  
Cell culture preparation: 
Cells in 1 well of a 6 well cell culture plate were homogenized with 700µl of Qiazol.  
1ug of RNA was used for cDNA synthesis using Super Script Reverse Transcriptase II (Invitrogen, 
Carlsbad, California, order no 18064-014) and random hexamer primers (Roche, Basel, Switzerland, order 
no 11277081001). Fast SYBR Green Master Mix (Applied Biosystems, Carlsbad, California, order no 
4385612) was added to the cDNA. qPCR was performed using the Step One Plus qPCR machine 
(Applied Biosystems, Carlsbad, California, order no 4376600). 
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Relative expression levels for each gene of interest were calculated using the ΔΔCt method and 
normalized to the expression 18S ribosomal RNA (18SrRNA). 
 
Semi quantitative real time PCR primers 
 
Primer name Sequence 5’ => 3’  
18S rRNA-F AGTCCCTGCCCTTTGTACACA   
 
18S rRNA-R CGATCCGAGGGCCTCACTA  
 
Cox5b-F GCTGCATCTGTGAAGAGGACAAC 
Cox5b-R CAGCTTGTAATGGGTTCCACAGT 
Cpt1-F ATCATGTATCGCCGCAAACT 
Cpt1-R CCATCTGGTAGGAGCACATGG 
Cycs-F GCAAGCATAAGACTGGACCAAA 
Cycs-R TTGTTGGCATCTGTGTAAGAGAATC 
Errα-F GCAGGGCAGTGGGAAGCTA 
Errα-R CCTCTTGAAGAAGGCTTTGCA 
GFP-F TCGAGGTGGTGTACATGAACGA 
GFP-R GCTGTAGAACTTGCCGCTGTT 
Mcad-F AACACTTACTATGCCTCGATTGCA 
Mcad-R CCATAGCCTCCGAAAATCTGAA 
MhcI-F 
 
CCTCCTCACATCTTCTCCATCTCT 
MhcIIA-F 
 
CCCCGCCCCACATCTT 
MhcIIA-R TGACTGATTCTCCCTGTCTGTTAGC 
MhcIIB-F CAACCCATATGACTTTGCTTACGT 
MhcIIB-R TCCCAGGATATCAACAGCAGTGT 
MhcIIX-F GAAGGAGAAGTGGAAAATGAACAGA 
MhcIIX-R TGTTTGCGCAGACCCTTGA 
MhcI-R TGGACTGATTCTCCCGATCTG 
PGC-1α_ex2-F TGATGTGAATGACTTGGATACAGACA 
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PGC-1α_ex2-R GCTCATTGTTGTACTGGTTGGATATG 
PGC-1α_ex3-5-F AGCCGTGACCACTGACAACGAG  
PGC-1α_ex3-5-R GCTGCATGGTTCTGAGTGCTAAG  
PGC-1β-F GGCAGGTTCAACCCCGA  
PGC-1β-R CTTGCTAACATCACAGAGGATATCTTG  
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5.4. Results 
 
 
Design and cloning of shRNAs to knock down PGC-1β 
 
Mouse PGC-1β, NM_133249 has 3 isoforms; two of which have the most widespread tissue distribution. 
Isoform1, Ppargc1b-001 hast 12 exons; isoform 2, Ppargc1b-002 has 13 exons. The third isoform is not 
protein coding and contains only 2 exons (table4).  
Thus, the shRNAs against PGC-1β should be designed to target both isoforms 1 and 2: 
 
Isoform Transcript ID Length 
(base 
pairs) 
Number of exons Protein ID Length 
(amino 
acids) 
Coding 
properties 
Ppargc1
b-001 
ENSMUST0000
0075299 
3656 12 ENSMUSP000
00074771 
1014 Protein coding 
Ppargc1
b-002 
ENSMUST0000
0063307 
3330 13 ENSMUSP000
00069431 
1030 Protein coding 
Ppargc1
b-003 
ENSMUST0000
0142134 
366 2 - - No protein 
product 
 
Table4: PGC-1β, NM_133249 isoforms: Exon composition, length on mRNA and protein level 
We strived for generation of shRNA-mir to make sure that the constructs enter the knockdown cascade at 
a very early stage (for more ample information, see introduction): For this purpose, we used 3 constructs: 
Both constructs1 and 2 were designed according to pri-miRNA design rules to form imperfect hairpin 
structures, containing nucleotides deletions, insertions and exchanges. Construct3, on the other hand was 
designed as conventional, perfect-match hairpin. For ease of designation, all constructs hereafter – 
irrespective of their design principles - will be termed as “shRNA”, numbered 1-4. 
 
Construct1:  
The most studied miRNA is human micro RNA-30; its precursor, more specifically the pri-miR-30 stem 
loop should be used as template to insert shRNA driven by a polymerase II or polymerase III promoter
178
. 
shRNA1 targets exon 11, shRNA2 targets exon 6 of PGC-1β: 
 
shRNA1: 
target sequence: 5’ ATACACTGACTATGATCCC 3’  
 
5‘TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCACACTGACTATGATCCCACATTAGTGAAGCCAC
AGATGTAATGTGGGATCATAGTCAGTGTA TGCCTACTGCCTCGG 3’ 
 
shRNA2:  
target sequence: 5’ GTCCTCTGAGGCTGGAGGT 3’  
 - 69 - 
 
5‘TCGAGAAGGTATATTGCTGTTGACAGTGAGCGCCCTCTGAGGCTGGAGGTGAAATAGTGAAGCCA
CAGATGTA TTTCACCTCCAGCCTCAGAGGA TGCCTACTGCCTCGG 3‘ 
 
scra shRNA:  
5‘ TCGAGAAGGTATATTGCTGTTGACAGTGAGCG GGAACAATCAGCATCCCGACCG 
TAGTGAAGCCACAGATGTA CGGTCGGGATGCT GATTGTTCCTGCCTACTGCCTCGG 3‘ 
 
(red: mRNA sense sequence, green: mRNA antisense sequence; blue: loop; black: flanking sequences; orange: 
shRNA enhancing, changed or added nucleotides; yellow background: original shRNA targeting sequence; bold font: 
nucleotides that were exchanged or added) 
 
Construct2:  
We also used the pri-miR-30 to generate shRNA which contains the stem loop structure and even more 
 extensive flanking sequences. For this purpose, we used the pMan vector
179
.  
Design was carried out according to: http://www.dharmacon.com/Home.aspx?id=642 
shRNA3 targets exon 9 of PGC-1β. 
 
shRNA3:  
target sequence: 5’ GCTTTGAGGTGTTCGGTGA 3’  
 
5‘TGCTGTTGACAGTGAGCGAGCTTTGAGGTTCGTTCGGGTGAGTGAAGCCACAGATGTCACCGAAC
ACCTCAAAGCCTGCCTACTCCTCGGACTTCAAGG 3’  
 
scra shRNA:  
5‘TGCTGTTGACAGTGAGCGAAACAATCAGCTCATCCCGGACCGTGAAGCCACAGATGGGTCCGGGA
TGAGCTGATTGTTTCTGCCTACTCCTCGGACTTCAAGG 3’  
 
Construct3:   
We then wanted to compare the knockdown potential of the first two constructs to a control shRNA 
already tested embedded in the pSuper vector: www.oligoengine.com/products/pSUPER.html
180
.  
shRNA4 targets exon6 of PGC-1β. 
 
shRNA4: 
Target sequence: 5’ GATATCCTCTGTGATGTTA 3’ 
 
5 AGCTTGATCCCCGATATCCTCTGTGATGTTATTCAAGAGATAACATCACAGAGGATATCTTTTTA 3 
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(A)…     (B)     (C) 
Fig.8: The three constructs used for embedding shRNA: (A): construct1: pri-miRNA
178
, (B): construct2: pri-
miRNA
179
, (C): construct3: shRNA
180. 
 
Fig11: shRNA target stretches from PGC-1β sequence, mus musculus, NM_133249, adapted from Ace View: 
http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/. Blue denotes intronic parts; green denotes exonic parts.  
 
Sequences in yellow, red and pink constitute targets of different shRNAs: 
 
shRNA name Sequence target 
shRNA1- pU6mir backbone Exon 11 
shRNA2- pU6mir backbone Exon 6 
shRNA3- pMan backbone Exon 9 
shRNA4-pSuper backbone Exon 6 
 
 
Optimization of transfection method and transfection quantity 
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In order to ascertain which cell culture model should be used for cell culture transfections, HEK293t and 
C2C12 myoblasts were transfected with 5ug GFP-pcDNA3.1(+) vs 5ug of pcDNA3.1(+) each. Calcium 
chloride method revealed to be most efficient in HEK293t cells and yielded around 70% transfection 
efficiency (Fig.12).  
 
 
 
Fig.12: transfection efficiency of calcium chloride transfection method in C2C12 myoblasts and HEK293t cells 
Plasmids carrying pcDNA3.1(+) or GFP-pcDNA3.1(+). Fluorescence analysis of cells 48hrs posttransfection. 
 
The next step was to determine the necessary transfection quantity of PGC-1β plasmid: Different amounts 
of PGC-1β plasmid were transfected: 5ug of PGC-1β (data not shown) was regarded as sufficient quantity 
and used in further experiments (Fig.13). 
 
 
Fig.13: evaluation of necessary quantity of PGC-1β for transfection 
HEK293t cells were transfected with different quantities of PGC-1β-pcDNA3.1(+) plasmid. Western Blot was done 
using anti FLAG antibody. 
 
 
Testing the efficiency and specificity of shRNAs against PGC-1β 
 
shRNA knockdown efficiency was subsequently tested using PGC-1β-FLAG plasmid cotransfected with 
different shRNA constructs. shRNA2pU6mir was found to be the most efficient knockdown construct 
(Fig.14). 
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Fig.14: shRNA constructs to knock down PGC-1β  
HEK293t cells were cotransfected with PGC-1β-FLAG plasmid together with shRNA constructs cloned in different 
plasmid backbones:pU6mir, pSuper and pMan carrying Pol III (U6), Pol III (H1) and Pol II (SV40) promoters, 
respectively. The molar ratio between the shRNA : PGC-1β used was 4:1. Protein extracts were harvested 48hrs post 
transfection. Western Blot against FLAG and α-Tubulin. 
 
insert backbone promoter 
shRNA1, 
shRNA2 
pU6mir-30 Pol III  (U6) 
shRNA3 pMan Pol II  (SV40) 
shRNA4 pSuper  Pol III (H1) 
PGC-1β 
plasmid 
pcDNA 3.1 Pol II (CMV) 
 
Table5: shRNAs and the respective vector backbones they are embedded in 
 
As the different shRNA constructs are embedded in different vector backbones driven by different 
promoters, their knockdown efficiency cannot be compared as such (Table5). The shRNAs that led to a 
visible knockdown were thus cloned into pcDNA3.1(+).  In this backbone, shRNA2 and shRNA4 were 
found to be the most efficient constructs in knocking down PGC-1β (Fig.15).  
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Fig.15: shRNA knockdown efficiency comparison of different constructs 
shRNA2, scrashRNA and shRNA4 cloned into pcDNA3.1(+) backbone under the CMV, a Pol II promoter. HEK293t 
cotransfection. Western Blot against FLAG and α-Tubulin. 
We next wanted to rule out possible off target effects of shRNA2 and shRNA4 against PGC-1α. 
Consequently, we cotransfected shRNA2 and shRNA4 with PGC-1α plasmid. As shRNA4 seemed to not 
only reduce the protein level of PGC-1β, but concurrently the level of PGC-1α, shRNA2 was used in 
further experiments. (Fig.16). 
 
Fig.16: Testing off target effects of shRNA against PGC-1α  
HEK293t cotransfection of the indicated shRNAs together with PGC-1α. Western Blot against FLAG and α-tubulin.  
 
Cloning of shRNA2 and scrashRNA into pAAV backbones 
 
shRNA2 and scrambled shRNA were consequently cloned into the backbones that are necessary for 
production of AAV2: The commercially available kit AAV helper free system from Agilent was used. Again, 
the knockdown efficiency of shRNA2 was tested in this new backbone (Fig.17). 
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(A)            
 
 
(B) 
 
Fig.17: Cloning map of pAAV-shRNA2-CMV and pAAV-CMV-scrashRNA plasmids (B) and shRNA2 knockdown 
efficiency testing in pAAV-CMV-MCS backbone (A). (B): amp= ampicillin resistance, R-ITR, L-ITR= left and right 
internal repeats, pCMV= CMV promoter, Hind III= restriction sites, hGH polyA= human growth hormone poly A 
sequence.  
 
AAV production and purification 
 
As shRNA2 also led to knockdown in the pAAV-CMV-MCS backbone, it should be used for production of 
AAV2 by triple transfection. To determine optimal production conditions, we also produced AAV-GFP-
IRES: 
First, we wanted to assess the morphological changes upon triple transfection: As indicated in the kit, cells 
detach and round up during AAV2 production (Fig.18A) when 3 Mio AAV293 cells are seeded. Second, 
we ascertained how many cells to seed for highest transgene (GFP) expression: Using 3 Mio cells 
resulted in best cell detachment and morphological changes associated with virus production. 
Consequently, AAV2 of shRNA2 and scrashRNA were produced using 3 Mio AAV293 cells. The 
morphology however did not closely resemble the morphology seen for GFP but showed clear signs of cell 
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death and debris formation in the case of shRNA2 production. (Fig.18B).Yet this phenomenon could be 
avoided by increasing the number of transfected cells to 4 million. Titer was then checked on the crude 
viral preparations using Cell Biolabs ELISA titration kit for AAV2 (Table6). 
 
 
(A) 
 
(B) 
Fig.18: production of AAV2 using Agilent’s AAV Helper Free System:  
(A) Triple transfection of 2, 3 or 4 Mio AAV293 cells with pAAV-GFP-IRES, pHelper and pCap2. Quantification via 
fluorescence microscopy 72hrs post transfection. (B) triple transfection of 3 Mio AAV293 cells with pAAV-GFP-IRES, 
pHelper and pCap2, 24hrs and 72hrs post transfection, respectively compared to triple transfection of pAAV-CMV-
shRNA2 24hrs posttransfection. Fluorescence analysis. 
 
samples Titer [VG/ml] 
shRNA2- 
2 mio cells 
5.8.10
9
 
shRNA2- 
3mio cells 
5.7. 10
9
 
shRNA2- 
4mio cells 
6.7. 10
9
 
scrashRNA- 
2mio cells 
5.5. 10
9
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scrashRNA- 
3mio cells 
4.8. 10
9
 
scrashRNA- 
4mio cells 
6.5. 10
9
 
 
Table6: titration of AAV2 produced with pAAV-CMV-shRNA2 and pAAV-CMV-scrashRNA constructs 
employing 2, 3 and 4 Mio AAV293 cells each. 
Prior to testing AAV2 in vivo, in vitro experiments should be carried out to confirm the knockdown of PGC-
1β. For this purpose, C2C12 cells were used as the virus should ultimately be injected in mouse skeletal 
muscle. C2C12 myoblasts were employed as they are undifferentiated and thus easier to transduce than 
differentiated C2C12 myotubes. C2C12 myoblasts were transduced with different quantities of AAV2-
GFP-IRES. 50 hrs post transduction, C2C12 myoblasts were assessed for fluorescence, which revealed 
that they did not take up the virus (Fig 19A).  
As C2C12 cells constitute one of many cell culture models of skeletal muscle, other models were also 
tested: Differentiated C2C12 cells, Sol8 and primary mouse skeletal muscle cells were transduced with 
AAV2- GFP-IRES, however, none of these cellular models seemed to take up the virus (data not shown). 
To assess if the virus was functional at all, a cell line from another tissue was used. This cell line had 
already been successfully transduced with AAV2
181
. The transduction of HEK293 cells with AAV2-GFP-
IRES was successful, but produced a moderate transduction of about 20% of cells only using 1000µl of 
virus (Fig.19B). This quantity seemed to be insufficient to check if exogenously added murine PGC-1β 
expression is downregulated by the AAV2-CMV-shRNA2. 
 
  
(A)            (B) 
Fig.19: transduction of C2C12 myoblasts (A) and HEK293 cells (B) with different quantities of crude 
preparations of AAV2-GFP-IRES 
Consequently, in order to increase the transduction efficiency of HEK293 cells, AAV2 was subjected to 
purification using Fast Trap Adeno Associated Virus (AAV) Purification and Concentration Kit from 
Millipore which is based on cation-exchange chromatography. Purification yields around 1ml of functional 
virus. For this reason, AAV2 was not titrated after this procedure but directly used for transducing cells: 
HEK293 and C2C12 cells were transduced with different amounts of AAV2-GFP-IRES. Both cell lines took 
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up the virus this time, with HEK293 taking up more than C2C12 myoblasts (Fig.20). The transduction 
efficiency, however, amounts to only about 30% in HEK293. 
Therefore, AAV2 should be tested directly in vivo without prior in vitro experiments.  
 
 
Fig.20: Transduction of HEK293 and C2C12 myoblasts with different quantities of purified AAV2-GFP-IRES. 
Fluorescence microscopy 50hrs posttransduction. 
 
AAV2/6 production, purification, titration and injection into mouse tibialis anterior (TA) 
 
AAV2/6 was produced with the AAV production core facility in the Institut de Recherche Thérapeutique, 
Université de Nantes, INSERM U649.  
Viral titer was determined at INSERM U649 using two strategies: First, mouse embryonic fibroblasts were 
transduced and the degree of infection used as a means to quantify functional virus. Second, capsid 6 
presence was quantified using enzyme linked immunosorbent assay (ELISA) technique, as a means to 
quantify the number of virions. As infection efficiency is tissue specific, we used the titer generated with 
ELISA as guidance. 
We then wanted to address three major questions:  
 
1. How much virus has to be injected into mouse TA in order to achieve considerable transgene 
expression?  
2. How long do we have to wait for efficient virus transduction? 
3. How long remains transgene expression on a stable level? 
4. Which is the most favorable route of delivery: local or systemic injection? 
 
AAV2/6- Route of delivery and virus quantity 
 
To address the first and second question, we locally injected mouse TA with 5x10E9 and 1x10E10 vector 
genomes (VG) of AAV2/6 carrying the GFP-IRES construct as recommended by Paul Gregorevic, Baker 
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IDI: AAV2/6-GFP-IRES was injected into the right leg and phosphate buffered saline (PBS) into the left leg 
as control setting. We then waited for 7, 14 and 21 days, respectively before extracting the TA. 
Fluorescence microscopy revealed that GFP expression was most prominent at 14 or 21 days 
postinjection, respectively. Both quantities, 5x10E9 and 1x10E10 VG worked for efficient transduction 
(Fig.21A).  
To carry out systemic tests on the injected animals (glucose tolerance test, insulin tolerance test, exercise 
performance test) we needed to know how long transgene expression remains on a stable level (third 
question). For this purpose, we would have had to do a timecourse sacrificing mice not only 7, 14 and 21 
days postinjection but until at least 2 months postinjection as AAV expression can persist for several 
months. In fact, according to Zincarelli, expression of both AAV2 and AAV6 seems to stabilize around day 
50 to day 80 which would thus constitute the ideal timeframe for experiments
174,182
. 
 
However, injection timecourses would only make sense if the construct of interest (shRNA2, scrashRNA) 
is used for this purpose, because due to the different properties of GFP, its detection can only be used as 
a proof of principle. As the amount of available AAV2/6-CMV-shRNA2 as well as of  AAV2/6-CMV-
scrashRNA was limited, we decided to only extend our expression test to 21 days postinjection, as this 
was the presumed peak of AAV6 expression (see also Fig.21A)
174,182
. 
  
Systemic injection was also tested as route of delivery. For this purpose, 2x10E10 VG (=200μl) were 
injected into mouse tail vein, IV (=intravenous injection). AAV2/6 expression was strongest in liver, heart 
and soleus, in line with Zincarelli’s observations
120
. Intraperitoneal (=IP) injection was tested as another 
route for systemic delivery: 5x10E10 VG (= 500μl) of AAV2/6-GFP-IRES were injected. As seen in the IV 
injection, expression was most pronounced in liver and heart as well as in lung. Skeletal muscle displayed 
even less expression of GFP (Fig.21B). The quantities used for IV and IP injections are less than are 
generally used for this purpose; however, we could not concentrate the viral titer any further
174,182
.  
 
 
(A) 
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(B) 
Fig.21: Local, TA targeted (A) and systemic (B) injections of AAV2/6-GFP-IRES into mouse 
Injected quantities were 1x10E VG, 5x10E10 VG (A), 6x10E10 VG (IV) and 1.6x10E11 VG (IP) (B), respectively. (A) 
shows fluorescence microscopy after 7, 14 and 21 days, respectively. (B) shows semi- quantitative real time PCR 
measurements of different organs compared in their expression of GFP 14 days postinjection. IV= intravenously, tail 
vein injected. IP= intraperitoneally injected. One mouse was used per condition. 18SrRNA was used as housekeeping 
gene (HKG). 
 
 
Circadian expression of PGC-1α and PGC-1β in skeletal muscle 
 
PGC-1α and PGC-1β have long been known to be expressed in a circadian fashion in liver and skeletal 
muscle
81
. In the latter, both are expressed to a similar degree at around 1pm. 
We wanted to ascertain the degree of circadian expression of both coactivators in our setting to find a 
timepoint when both are expressed at a rather high level: This should help us to determine the timpoint 
when TA should be extracted in order to gain consistent results.  
Consequently, we sacrificed two C57BL/6 WT mice at 3 different timepoints and checked the coactivators’ 
expression levels in TA: PGC-1β levels remained rather stable throughout the day whereas PGC-1α 
expression was increased from 1pm to 4.30pm (Fig.22). We thus decided to extract TA in our future 
experiments starting around 9am as expression difference between PGC-1α and PGC-1β is smallest. 
Furthermore, by administering functional virus into the right leg and control virus into the left leg, we aimed 
at decreasing intra-individual expression differences. By sacrificing animals at a similar timepoint 
(9am), we further aimed at decreasing inter-individual expresssion differences due to circadian rhythm. 
 
 
Fig.22: mRNA expression levels of PGC-1α and PGC-1β throughout the day 
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C57 BL/6 mice were sacrificed at different timepoints and mRNA levels of PGC-1α and PGC-1β were measured via 
semi quantitative real time PCR. n=2; +SEM. 18SrRNA used as HKG. 
 
AAV2/6- effects on inflammatory response  
 
We next asked the question if AAV2/6 delivery fosters inflammatory response. First, immune respone due 
to AAV is tissue specific
183
. Second, it is increased in skeletal muscle that is already injured like in mdx 
mice which also display lower transgene expression originating from the virus
184
. 
We thus checked for signs of inflammation using WT mouse spleen as positive control setting. Staining of 
CD68 (macrophage marker) and CD3 (T cell marker) in TA showed that the difference between virus 
injected and PBS injected TA was not considerable (Fig.23B). 
Hematoxylin & eosin staining should reveal if there is muscle damage via yielding centrally localized 
nuclei. We did not detect these in TA that was treated with either scrashRNA or shRNA2 (Fig.23A). 
   
(A)         
 
(B) 
Fig.23: Evaluation of inflammatory and target gene effects of AAV2/6 mouse TA local injections: 
 (A) Immunohistochemistry: Hematoxylin & Eosin staining of mouse TA 28days postinjection with 5x10E9 and 
1x10E10 VG of AAV2/6-CMV-shRNA2-CMV or AAV2/6-CMV-scrashRNA. (B) Immunohistochemistry: CD68 and CD3 
of mouse spleen and TA, 14 and 28 days postinjection of AAV2/6-CMV-shRNA2, AAV2/6-CMV-scrashRNA or PBS 
injection into mouse TA.  
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AAV2/6- knockdown of PGC-1β- mRNA level  
 
As small scale testing of inflammatory response owing to injection or virus delivery proved negative, we 
proceeded to AAV2/6-CMV-shRNA2 and AAV2/6-CMV-scrashRNA injections into TA muscle of C57 BL/6 
WT mice: 28 days postinjection, mice were sacrificed and checked for gene expression levels of PGC-1α, 
PGC-1β and their downstream target genes. Whereas PGC-1α levels were not changed, PGC-1β as well 
as its target genes Cox5b, Errα, Cycs and Mcad (Acyl-CoA dehydrogenase) were significantly reduced 
(Fig.24). 
 
 
Fig.24: Evaluation of PGC-1β and target gene knockdown of AAV2/6 mouse TA local injections 
AAV2/6 injections into mouse TA using 1x10E VG AAV2/6-CMV-shRNA2 or AAV2/6-CMV-scrashRNA as control. 
Effect on gene expression levels of PGC-1α, PGC-1β and its target genes measured via semi-quantitative real time 
PCR. TA extraction was done 21 days postinjection. n=6; +SEM; paired, 2-tailed T test was used to calculate p value. 
p≤0.05=*; p≤0.01=**; p≤0.001=***. 18SrRNA was used as HKG. 
 
AAV2/6- shRNA2- GFP construct 
 
The construct used so far has been AAV2/6-shRNA2-GFP. The AAV Helper Free System Manual 
however indicates that there is not only a maximum insert size of 3kB but also a minimum insert size of 
1kB in order to guarantee efficient viral packaging. We thus added a “DNA stuffer sequence” of about 
700BP in the form of GFP. We thus hoped to avoid a possible loss of function of the shRNA due to 
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inefficient packaging. Even though, we did hardly see any difference in shRNA efficiency comparing the 
AAV2/6-shRNA2 and AAV2/6-shRNA2-GFP constructs in vivo (Fig.25). 
 
       
(A)                 (B) 
Fig.25. AAV2/6-CMV-shRNA2 vs AAV2/6-CMV-shRNA2-GFP 
(A) AAV2/6 injections into mouse TA using 1x10E VG AAV2/6-CMV-shRNA2 and AAV2/6-CMV-shRNA2-GFP with 
AAV2/6-CMV-scrashRNA and PBS as control settings. Effect on gene expression levels of PGC-1α, PGC-1β and its 
target genes measured via semi- quantitative real time PCR. TA extraction was done 28 days postinjection. n=1. 
18SrRNA was used as HKG. (B) cloning map of AAV2/6-CMV-shRNA2-GFP construct: Bgl II = Bgl II restriction sites 
 
AAV2/6- knockdown of PGC-1β- protein level  
 
We then wanted to see if this downregulation on the mRNA level translated into diminished protein levels 
of PGC-1β. Thus far, no commercially available antibody against PGC-1β that worked in tissue had been 
characterized. We thus tested a range of PGC-1 antibodies: 
The PGC-1 antibody from Chemicon (Millipore) was found to be the most reliable one in detecting 
overexpressed PGC-1α and PGC-1β in cell culture extracts (Fig.26). 
 
         
Fig.26: PGC-1/ PGC-1β antibody test: in vitro samples  
HEK293 cells were transfected with 5ug of PGC-1α (α) or PGC-1β (β) plasmids. 48hrs afterward, protein extract was 
prepared. 80ug of protein loaded on Western Blot. PGC-1α: 90kDa, PGC1β: 110kDa  
PGC-1β 
PGC-1α 
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We subsequently tried to ascertain how the PGC-1 antibody from Chemicon behaved when using samples 
from tissue: The samples that contained overexpressed PGC-1α and PGC-1β were detected at the right 
sizes; the PGC-1 antibody however did not detect either PGC-1 in skeletal muscle: TA, gastrocnemius, 
soleus and extensor digitorum longus (EDL) did not yield any band that seemed to be specific (Fig.27). 
For this reason, we did not try to further detect shRNA2 mediated knockdown of PGC-1β via AAV2/6 on 
the protein level. 
 
         
Fig.27: PGC-1/ PGC-1β antibody test: in vivo samples  
lanes 1-2: HEK293 cells were transfected with 5ug of PGC-1α or PGC-1β plasmids. 48hrs afterward, protein extract 
was prepared. Lanes 3-6: Skeletal muscle tissue from 5 month old C57 BL/6 WT mice: TA, gastrocnemius, soleus, 
EDL. 80ug of protein loaded on Western Blot.  
 
AAV2/6- skeletal muscle specific promoter 
 
Thus far in this project, injection of shRNA to knock down PGC-1β has only been done locally, in TA 
muscle. Systemic injection however allows for measurement of systemic parameters that change upon 
reduction of PGC-1β: We therefore aimed at constructing a virus carrying a shRNA driven by a skeletal 
muscle specific promoter suitable for systemic injection.  
We cloned the shRNA2/ scrashRNA constructs plus flanking sequences into the pAAV plasmid containing 
the skeletal muscle specific creatine kinase6 (CK6) promoter, respectively and tested their potency 
directly in vivo: Prior to the planned systemic injection, we wanted to test promoter strength via local 
injection: TA was injected with AA2/6-shRNA2/ scrashRNA- CK6 at 1x10E10 VG: 14 and 28 days 
postinjection, TA was isolated and analyzed for PGC-1α, PGC-1β and its target gene Errα. Neither of 
them was changed significantly. This result implies that promoter strength of this tissue specific promoter 
may not be strong enough for driving shRNA expression (Fig.28). 
 
PGC-1α 
PGC-1β 
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(A) 
   
(B) 
Fig.28: AAV2/6-shRNA2 or scrashRNA-CK6 injection into mouse TA 
(A) Gene expression levels of PGC-1α, PGC-1β and its target gene Errα were measured by semi quantitative real 
time PCR 14 and 28 days postinjection, respectively. 18SrRNA was used as HKG. n=3; +SEM. (B) cloning map of 
pAAV-CK6-shRNA2 and pAAV-CK6-scrashRNA. Sac I and Bsm I were the restriction enzymes used.  
 
 
AAV2/6- effects of PGC-1β knockdown on fiber type distribution 
 
With systemic injection being hampered by promoter properties, we still wanted to know if the decrease in 
PGC-1β expression levels seen after local TA injections using AAV2/6-CMV-shRNA2 has implications on 
fiber type composition: We thus looked at fiber type composition via expression levels: Given a significant 
reduction of PGC-1β levels, we would expect a decrease in IIX fibers. 
There seemed to be a reduced expression in MhcI, IIa, IIb and IIx fibers in the AAV2/6-CMV-shRNA2 
injected TA. However, none of these reductions proved to be significant (Fig.29). 
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Fig.29: Fiber type expression pattern in TA of AAV2/6-CMV-shRNA2-CMV or AAV2/6-CMV-scrashRNA injected 
mice 
Measurement of MhcI, IIa; IIb and IIx by semi-quantitative real time PCR. 4 weeks postinjection. 18SrRNA was used 
as HKG. n=5; +SEM 
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5.5. Discussion 
 
In this project, we used AAV to deliver an RNAi construct against the coactivator PGC-1β into mouse 
skeletal muscle: We decided upon AAV2 pseudotyped with capsid 6 (AAV2/6) due to its low 
immunogenicity in the host and skeletal muscle specific expression of the construct.  
Regarding the construct employed, we strived to develop different RNAi molecules: one conventional 
shRNA (pSuper backbone) and two pri-miRNAs (pU6mir and pMan backbones), the two latter of which 
integrate into the silencing pathway higher upstream to enhance knockdown potency and limit toxicity
185
.  
The AAV2/6 construct was then injected into mouse via systemic (intraperitoneal, intravenous) as well as 
local (intramuscular) injection. We also compared the use of two Polymerase II promoters, a ubiquitously 
expressed (CMV) and skeletal muscle specific (CK6) promoter to restrict shRNA expression to skeletal 
muscle. 
Finally, we studied the effect of the knockdown on the morphological (H&E staining, inflammatory markers 
CD3 and CD68 staining) and gene expression level (semi-quantitative real time PCR of target genes). 
 
Design of shRNAs against PGC-1β 
 
As mentioned above, there is a plethora of different shRNA design tools and strategies available the 
comparison of which would constitute a project of its own. In our design rationale, however, we had to 
respect in vivo requirements and applicability: It would have been tempting to use a wide array of different 
siRNA molecules to rapidly check knockdown efficiency prior to the more time consuming cloning steps. 
Yet, as our shRNAs and pri-miRNAs respect specific design criteria within the target sequence (exchange 
or removal of nucleotides), their effect cannot be compared to classical siRNA. We finally achieved a 
knockdown level of about 60% in vitro employing shRNA2 driven by the CMV promoter (Fig.15). 
Comparing the different shRNAs in their knockdown potency seemed all the more important as shRNA4 
produced the strongest knockdown. If all constructs were driven by the same promoter, however, it fared 
as well as shRNA2 and much worse regarding the off target effects towards PGC-1α.  
 
Testing the efficiency and specificity of shRNAs against PGC-1β 
 
The testing of efficiency and specificity of the different shRNAs (1-4) against PGC-1β was evaluated 
exclusively on the protein level (Fig.14): It would have been interesting, though, to prove the knockdown 
effects also on the gene expression level via semi-quantitative real time PCR. We thus designed specific 
primers to detect the knockdown of PGC-1β; however we did not see consistent decrease in the mRNA 
levels of PGC-1β of shRNA treated cells (unpublished data). shRNAs lead to mRNA degradation as well 
as translational repression which may render the detection of decreased mRNA levels difficult
157
. 
However, recent evidence indicates that the predominant way of shRNA action is via mRNA 
degradation
186
.  
 - 87 - 
 
AAV transduction 
 
Although C2C12 myoblasts have already been successfully transduced with AAV2
187
, our transduction 
approach was less successful (Fig.19): Other skeletal muscle cell culture models used like Sol8 or 
primary cells also could not be transduced. Only HEK293 cells took up the virus to a certain extent. 
Purification increased transduction efficiency for both C2C12 myoblasts and HEK293 cells; however it was 
still modest (Fig.20). A more potent transduction ratio would have necessitated upscaling of viral 
production and reliable titration of functional virus. We thus decided to have AAV2 produced with a 
company specialized in AAV production and purification (INSERM U649, Institut de Recherche 
Thérapeutique, Nantes). Among the three rounds of viral production that they did, one delivered rather low 
titers owing to increased cell lysis and degradation during AAV production: We thus concluded that shRNA 
toxicity may be responsible for these effects witnessed by two independent production processes.  
 
shRNA and AAV toxicity 
 
Among AV, LV and AAV, the latter is known for inciting least immunogenicity
188
.  
shRNA toxicity effects can emanate from three factors: first, the viral vector used, second, the hairpin used 
or third, the target sequence responsible for silencing:  
Toxicity associated with hairpin structure may have been an issue, although embedding the shRNA into 
the pri-miRNA structure as well as the polymerase II promoter used should be able to mitigate this 
nocuous effect
159,185
. The fact that the increase in AAV293 producing cells for AAV production attenuated 
the toxic response may be indicative of a dose dependent effect of shRNA toxicity. Consequently, we 
were concerned that this in vitro phenomenon could recur in vivo and decided to use the lowest titer 
possible on a small number of animals for the first in vivo experiments.  
 
AAV delivery  
 
In vivo viral injections require optimization on a myriad of different levels: quantity, route of delivery, 
incubation time to identify time of peak expression and the therapeutic window when viral titer remains 
constant over a given time. The latter point is especially important if one considers doing systemic tests 
after viral delivery. 
We soon realized that these variables not only interrelate and thus cannot be answered satisfactorily, but 
also that it would require much more virus to do serious time course studies to pinpoint maximum 
expression levels. With 1-3 animals injected per condition, no reliable statement about the knockdown 
level of PGC-1β and its target genes could be made.  
Systemic injection would have been the delivery route of choice. But owing to the insufficient titer levels for 
this procedure, we could not pursue this strategy further. Even companies specialized in AAV production 
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and purification do not seem to have solved this problem of concentrating AAV further (oral 
communication, Françoise Balter, INSERM U649, Institut de Recherche Thérapeutique, Nantes). 
  
Promoter usage 
 
Systemic injection can be considered if a tissue specific AAV serotype, as the AAV6 that was used for 
pseudotyping in our case is available. Another strategy would be to use a tissue specific promoter as the 
CK6 promoter in our case. Prior cell culture testing of such a promoter is a cost and time saving 
procedure. However, there is a major drawback regarding the testing of skeletal muscle specific promoters 
in cell culture models: Many growth factors, developmental and physiological stimuli cannot be mimicked 
in cell culture conditions. One study points out the difference in skeletal muscle promoter efficiency in vitro 
versus in vivo systems
189
.  We thus decided to test our CK6 driven construct immediately in vivo. 
Unfortunately, the CK6 promoter revealed to be less efficient than projected and we exclusively employed 
the CMV promoter for our studies. 
 
PGC-1β knockdown and PGC-1α KO: global versus local 
 
We initially strived for a model that would permit PGC-1β knockdown in a skeletal muscle specific PGC-1α 
deficiency mouse model. Unfortunately, due to breeding problems, we could not establish such a model 
during the course of this PhD project. 
 
A project oriented towards a similar goal was conceived and published by Zechner et al recently
150
: 
Ablation of both PGC-1 isoforms compared to the absence/ reduction of either PGC-1α or PGC-1β should 
shed light on the overlapping/ common targets of both isoforms as well as on the specific role of PGC-1β 
in skeletal muscle: A skeletal muscle specific ablation of PGC-1β was combined with a global ablation of 
PGC-1α and described as a model of double skeletal muscle specific knockout: These animals show no 
signs of altered insulin sensitivity both on chow and HFD. This result should be viewed with caution 
though: PGC-1α global knockout mice have different plasma glucose levels than skeletal muscle specific 
PGC-1α knockout mice, which is probably due to organ cross talk between the pancreas and skeletal 
muscle
13
. 
Regarding fiber type composition, Zechner’s double KO animals display an increase in typeI fibers; the 
number of IIX fibers that are typically induced by PGC-1β though does not change. In this case, the global 
PGC-1α KO mice also behave differently from the skeletal muscle specific PGC-1α KO animals: The first 
do not undergo fiber type switch to typeI fibers, whereas the latter do.  
Consequently, for PGC-1α and most likely also PGC-1β, the global knockout model cannot substitute for a 
tissue specific knockout model
121
. 
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The importance of PGC-1β in glucose homeostasis was underlined by another article that appeared 
recently: Wright et al overexpressed PGC-1β in skeletal muscle: On HFD, the treated mice displayed 
ameliorated insulin sensitivity along with decreased levels of long-chain acyl-CoAs (LCACoAs) and 
increased antioxidant defenses
148
. 
 
Technical prospects 
 
Despite construct design and delivery optimization efforts, we ultimately only achieved a knockdown of 
about 60% for PGC-1β.  
Optimizing vehicle (AAV) and construct (shRNA) structure may help increase KD efficiency: 
 
Vehicle optimization 
 
We could have increased the amount of functional virus delivered to 5x10E10 or 1x10E11 VG via 
repeated injections: Even though, this strategy should be avoided: A subset of the human population 
shares antibodies against AAV2 which may neutralize AAV2 that is subsequently injected
190
. Although a 
similar phenomenon has not been described for mice, this possibility should not be discarded. As possible 
AAV antibodies are directed against the capsid, re-administration of a different serotype would help avoid 
this problem. However, capsid exchange also changes tissue tropism which would enhance uptake in 
tissues other than muscle.  
 
The first AAV constructs that were developed exploited the single strand usage of the AAV genome. This 
single strand has to be replicated into a double strand DNA molecule prior to being transcribed by the host 
polymerase, explaining why the onset of transcript expression from AAV takes so long. A more recent 
development in AAV design circumvents this time lag: self- complementary AAV (scAAV) contains an ITR 
that links the sense target sequence to its complementary sequence. scAAVs have 10 to 100 fold higher 
transduction ratios and a faster onset of expression than the classical AAV
191
. We thus could have 
employed this strategy to increase shRNA expression.  
 
Another avenue for enhancing expression of the transgene would be to coinfect TA muscle with the 
AAV2/6 carrying the shRNA together with an AAV containing enhancer elements for the CMV promoter 
used in AAV2/6. Through the interaction of enhancer and promoter, an increased transcription level can 
be achieved
192
. 
 
These two approaches seem to be attractive strategies at first glance. Still, an increase in shRNA 
expression is associated with increased toxicity hazard. Improving the shRNA sequence itself may thus 
prove to be a better alternative. 
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Construct optimization 
One approach to enhance RNAi efficiency is to express several miRNA hairpins
193
 by stacking together 
several shRNA molecules on one single hairpin (extended shRNA= e-shRNA molecules with 43 BPs in 
length 
162
). Double long hairpin RNAs (dlhRNA) exploit a similar principle by which two e-shRNAs are 
combined with each other, yielding four siRNAs upon processing
194
. 
 
There are thus ample options for improvement on both the construct and the delivery level. Finding the 
best solution for our specific case would well have been more time consuming than generating a mouse 
harboring a tetracycline/ tamoxifen inducible PGC-1β KO system. Furthermore, it is less cost intense to 
breed a sufficient amount of mice for experiments when using the PGC-1β KO system.    
It will still take some time until AAV and shRNA technology will have identified standard, hands-on and 
cost effective procedures for generating genetically modified animals. 
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5.6. Conclusions 
 
Project2 demonstrated that skeletal muscle specific reduction of PGC-1β leads to reduced expression of 
genes implicated in OXPHOS (e.g. Cox5b, Mcad, Cycs, Errα). Although the reduction in PGC-1β did not 
change skeletal muscle myosin heavy chain fiber types, both PGC-1α and PGC-1β thus seem to be 
important for skeletal muscle energy homeostasis. It is thus also worth considering to not only modulate 
PGC-1α levels for therapeutic purposes (prevention of atrophy), but also PGC-1β levels.   
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6. Perspectives 
 
The projects presented in this PhD thesis may seem at best remotely associated with each other via the 
studied coactivator PGC-1. However, they both converge in some regards: 
 
Global vs local, ablation vs reduction 
 
Project1 was based upon a global KO model, whereas in project2 a tissue specific KD should be 
generated:   
 
Although the global PGC-1α KO mice display a clear phenotype only in the challenged state
125,112
, we 
already observed some deviations from the WT mice in the basal condition: We were faced with 
diminished survival rates of homozygous PGC-1α KO mice offspring which may have been caused by an 
apparent dysregulation of body temperature. Also, among the surviving KO animals many mice failed to 
achieve WT bodyweight and size. 
For this purpose, it would have been advantageous to generate retina specific PGC-1α KO mice in 
project1. Owing to the great number of different retinal cell types, however, such an undertaking is hardly 
feasible.  
 
In project2, however, ablation of PGC-1β was localized to one single skeletal muscle, the TA: 
Unfortunately, the attempt to generate a skeletal muscle specific PGC-1β KD mouse was unsuccessful as 
the CK6 promoter did not work in our hands in vivo.  This is why we probably also did not witness any 
change in fiber type composition in knocking down PGC-1β as can be seen with PGC-1β 
overexpression
140
.  
 
Lipid metabolism 
 
Elucidating the function of PGC-1β in skeletal muscle was a main motivation in project2, as its role is best 
studied in liver to date. Lipid metabolism is also essential in retina: Poly – unsaturated fatty acids (PUFAs) 
are used for building up neurons’ cell membranes and have anti apoptotic properties
195
. Lipoprotein 
structures are responsible for taking up cholesterol into the retina
196
.  It would still be interesting to know if 
ablation of PGC-1β in retina has effects on retinal health.  
 
Compensatory effects 
 
An interesting observation in both projects is the possible compensatory effect of either PGC-1α or PGC-
1β in project2 or project1, respectively: It would not have been surprising if the global ablation of PGC-1α 
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had led to increase in PGC-1β in the light stress condition, which was not the case. Rather, both PGC-1s 
were downregulated in this setting. 
In skeletal muscle, PGC-1β reduction was quite small and thus compensatory increase of PGC-1α rather 
unlikely: In fact, PGC-1α was not changed significantly in this setting. 
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